

# Immunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring

Tisha Wang, M.D.,<sup>1</sup> S. Sam Weigt, M.D.,<sup>1</sup> John A. Belperio, M.D.,<sup>1</sup>  
and Joseph P. Lynch, III, M.D.<sup>1</sup>

## ABSTRACT

Treatment strategies for anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are evolving. Cyclophosphamide (CYC) plus corticosteroids (CSs) is the mainstay of therapy for generalized, multisystemic AAV. Historically, the combination of CYC plus CS was used for a minimum of 12 months, but concern about late toxicities associated with CYC has led to novel treatment approaches. Currently, short-course (3 to 6 months) induction treatment with CYC plus CS, followed by maintenance therapy with less toxic agents (eg, methotrexate, azathioprine, mycophenolate mofetil) is recommended. Further, methotrexate combined with CS may be adequate for limited, non-life-threatening AAV. Recent studies suggest that rituximab may be useful for induction therapy or for CYC-refractory AAV. This article reviews the key agents used to treat AAV, with a focus on pharmacology, toxicities, and monitoring.

**KEYWORDS:** Vasculitis, anti-neutrophil cytoplasmic antibodies, immunosuppressive medications, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, tumor necrosis factor inhibitors, rituximab, intravenous immunoglobulin G

Cyclophosphamide (CYC) plus corticosteroids (CSs) is the mainstay of therapy for generalized, multisystemic anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).<sup>1</sup> Historically, the combination of CYC plus CS was used for a minimum of 12 months,<sup>2,3</sup> but concern about late toxicities associated with CYC has led to novel treatment approaches. Recent regimens adopt an initial “induction phase” [to assure complete remission (CR)] followed by less intense “maintenance” therapy (to minimize long-term toxicities).<sup>2,4-6</sup> Currently, induction treatment with CYC plus CS has been considered optimal for severe AAV, but methotrexate (MTX) may be adequate for *limited, non-life threat-*

*ening* AAV.<sup>7,8</sup> Following induction of CR, less toxic agents [eg, MTX,<sup>6,8</sup> azathioprine (AZA)<sup>4,6</sup> or mycophenolate mofetil (MMF)<sup>1</sup>] may be substituted as maintenance therapy. This maintenance regimen is continued for a course of 12 to 18 months.<sup>2,5,6,9</sup>

CSs are invaluable as adjunctive therapy for AAV and rapidly gain control of inflammatory manifestations of the disease. However, CSs have myriad side effects,<sup>10</sup> and recent treatment strategies for AAV advocate more rapid taper and/or low dosages of CSs.<sup>1,11,12</sup> The toxicities, dosage regimens, and contraindications to CS use are well known to most physicians and will not be further discussed here.

<sup>1</sup>Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, California.

Address for correspondence and reprint requests: Joseph P. Lynch, III, M.D., Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, Department of Medicine, The David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Rm. 37-131 CHS, Los Angeles, CA 90095-1690 (e-mail: jplynch@

mednet.ucla.edu).

Lung Vasculitis and Alveolar Hemorrhage; Guest Editor, Loïc Guillevin, M.D.

Semin Respir Crit Care Med 2011;32:346-370. Copyright © 2011 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

DOI: <http://dx.doi.org/10.1055/s-0031-1279831>.

ISSN 1069-3424.

More aggressive therapeutic options [eg, intravenous (IV) pulse methylprednisolone (1000 mg daily) or plasma exchange] may have an adjunctive role in severe AAV [eg, rapid progressive glomerulonephritis (RPGN) or diffuse alveolar hemorrhage (DAH)].<sup>1,2,13,14</sup> These adjunctive therapies are not addressed here.

This review focuses on the key immunosuppressive agents used to treat AAV, with an emphasis on pharmacology, dosing, toxicities, and monitoring. The discussion is limited to those agents that are considered “standard” therapy for either induction (eg, CYC, MTX) or maintenance of remissions (eg, AZA, MTX, MMF) but includes the newer biologics [eg, rituximab,<sup>11,12</sup> tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) inhibitors,<sup>15,16</sup> intravenous immunoglobulin G (IV IgG)]<sup>17</sup> that have been utilized increasingly over the past few years. Diverse other agents have been associated with anecdotal successes in small series of patients with AAV (usually failing or experiencing adverse effects with standard therapy). These therapeutic options include leflunomide,<sup>18,19</sup> calcineurin inhibitors (eg, cyclosporine, tacrolimus),<sup>20</sup> rapamycin,<sup>21</sup> antithymocyte globulin (ATG),<sup>22</sup> etoposide,<sup>23</sup> 15-deoxyspergualin,<sup>24</sup> alemtuzumab (Campath-1H, a monoclonal antibody directed against CD52),<sup>25</sup> and monoclonal antibodies against T cells.<sup>26</sup> A discussion of these non-traditional agents is beyond the scope of this paper.

## CYCLOPHOSPHAMIDE

CYC (combined with CSs) has been the treatment of choice for severe or generalized vasculitis for more than 3 decades.<sup>2,4,27</sup> CYC has regulatory approval to treat diverse hematologic and nonhematologic malignancies and is used to treat a variety of autoimmune and inflammatory disorders.<sup>28,29</sup>

### Mechanism of Action

CYC, a prodrug derived from mechlorethamine, exerts protean and diverse effects on cellular and humoral immunity.<sup>29,30</sup> Effects include a dose-dependent reduction of B and T lymphocyte numbers and function, more pronounced reduction of CD4 and CD8 (+) subsets, suppression of T cell activation and B cell immunoglobulin production, bone marrow suppression (all cell lines), and neutropenia.<sup>28–30</sup> CYC is more toxic to the bone marrow than other immunosuppressive agents such as AZA, MTX, MMF, or leflunomide.<sup>28,30</sup>

### Dosage, Route of Administration, Pharmacology

CYC can be administered orally (dose 1 to 2 mg/kg/day)<sup>3,31</sup> or intravenously as a pulse (initial dose 0.50 to 0.75 g/m<sup>2</sup>) once monthly.<sup>27,30,31</sup> Because severe nausea and vomiting may complicate IV pulse CYC, we recom-

mend concomitant use of a 5-HT<sub>3</sub> antagonist antiemetic (eg, ondansetron) plus CSs, diphenhydramine, and/or lorazepam.<sup>29,32</sup> To avoid bladder toxicity, patients should drink at least 3 L of fluids during the 24 hours prior to treatment, and normal saline is given during the IV infusion to assure adequate hydration. Urine output should be maintained >100 mL/hr for 24 hours, and complete bladder emptying must be assured.<sup>29</sup> We recommend administering sodium 2-mercaptoethane sulfonate (MESNA) every 12 hours for 24 hours to minimize bladder toxicity.<sup>29</sup> MESNA binds acrolein and other toxic CYC metabolites in the urinary bladder.<sup>28</sup> The monthly dose of IV CYC needs to be adjusted to maintain the total leukocyte count nadir above 2000/mm<sup>3</sup>. In contrast, daily oral CYC dosing is titrated to maintain a total leukocyte count nadir above 3000/mm<sup>3</sup>. We limit the maximum IV CYC dose to 1 g/m<sup>2</sup>.<sup>2,29</sup> The frequency of IV pulse CYC may be reduced to every 3 months after a sustained remission has been achieved.<sup>30</sup> Both routes of administration (oral and IV) are equally efficacious in inducing remissions in AAV,<sup>1,31</sup> but relapses were more common with IV pulse CYC in some studies.<sup>33–35</sup> Oral CYC may be effective as rescue therapy for patients failing IV pulse CYC,<sup>27</sup> but additional agents (particularly biologics) may be required. Dose adjustments apply to both the oral and the IV routes, with lower doses given in the presence of renal failure, obesity, or inadequate bone marrow reserve.<sup>29</sup>

### Toxicity

CYC has myriad potential toxicities<sup>28–30</sup> (discussed in detail in the following sections). Intermittent high-dose IV pulse CYC may reduce toxicities compared with daily oral CYC (particularly hemorrhagic cystitis and bladder cancer) secondary to a lower cumulative dose.<sup>8,27,31,36</sup>

### Bone Marrow Suppression

CYC suppresses all cell lines within the bone marrow and is more toxic than other immunosuppressive agents (eg, AZA, MTX, MMF).<sup>28,30</sup> Maximum depression of circulating granulocytes and lymphocytes occurs within 7 to 14 days of a single dose of CYC,<sup>30</sup> though platelets are typically spared.<sup>37</sup> Chronic use (>1 year) may cause progressive lymphopenia, pancytopenia, and increased sensitivity to the drug.<sup>30</sup> Refractory pancytopenias may presage myelodysplastic syndrome or hematological malignancy.<sup>3,38,39</sup>

### Gastrointestinal Toxicity

Nausea and/or vomiting occur in >25% of patients receiving IV pulse CYC, but in <10% of patients receiving oral CYC.<sup>30</sup> Antiemetics (eg, ondansetron)

plus dexamethasone may alleviate these symptoms.<sup>32,40</sup> CYC-induced hepatotoxicity is rare (<1%).<sup>41,42</sup> Elevations in transaminases resolve rapidly upon withdrawal of CYC.<sup>41,42</sup>

### Pulmonary

Interstitial pneumonitis and progressive pulmonary fibrosis rarely complicate CYC therapy.<sup>30,43</sup> Cardinal histological features of pulmonary injury due to CYC (or other alkylating agents) include proliferating type 2 pneumocytes, cellular atypia, and varying degrees of interstitial inflammatory cells and fibrosis.<sup>30,43</sup> Given the rarity of pulmonary complications, screening with chest radiographs or pulmonary function tests (PFTs) is not necessary.<sup>28</sup>

### Infections

Chronic CYC therapy increases the risk of infections, including bacterial, viral (particularly herpes zoster),<sup>44</sup> and opportunistic infections.<sup>30,45</sup> Leukopenia, increasing age, deteriorating renal function, or concomitant use of CSs (especially dosages equivalent to >20 mg/day of prednisone) increases the infectious risk.<sup>30,45,46</sup> The cumulative dose of CYC has also been correlated with an increased infection risk.<sup>47</sup> Pneumonia due to *Pneumocystis jirovecii* (PCP) complicates CYC therapy in 2 to 10% of patients<sup>35,45</sup> in the absence of prophylaxis. For both oral and IV CYC, we recommend trimethoprim/sulfamethoxazole (T/S) 80/480 (one single strength tablet) thrice weekly for prophylaxis against PCP and nocardiosis.<sup>30</sup> Routine vaccinations should also be given and dose adjustments made for age and renal insufficiency to reduce episodes of CYC-induced leukopenia.<sup>48</sup>

### Hemorrhagic Cystitis and Carcinomas of the Bladder

Hemorrhagic cystitis complicates CYC use in 5 to 34% of patients and increases the risk of bladder fibrosis and carcinoma.<sup>3,30,39,49-51</sup> Acrolein, a metabolic of CYC, is considered to be the responsible toxin.<sup>50</sup> Clinical manifestations include microscopic or gross hematuria; rarely, massive, fatal hemorrhage has been reported.<sup>49,50</sup> Hemorrhagic cystitis is an absolute indication to stop CYC. CYC should *not* be reintroduced in *any* formulation even after symptoms resolve.

Transitional cell carcinoma develops in 2 to 15% of patients receiving long-term CYC.<sup>49,50,52,53</sup> The risk of bladder carcinoma is dose dependent and increases with duration of therapy.<sup>49,53</sup> Cumulative doses exceeding 50 g are associated with 6- to 14-fold increased risk<sup>49,51-53</sup>; cigarette smoking heightens the risk.<sup>49,52</sup> The risk of developing bladder cancer persists for years, even after cessation of CYC.<sup>49-53</sup> A long-term study of

146 patients with Wegener granulomatosis (WG) receiving chronic CYC identified seven cases of transitional cell carcinoma of the bladder.<sup>49</sup> Bladder cancer developed in six of 51 patients whose cumulative dose of CYC exceeded 100 g. By Kaplan-Meier analysis, the estimated incidence of bladder cancer following first exposure to CYC was 2% at 5 years, 5% at 10 years, and 16% at 15 years.<sup>49</sup> In a cohort of 416 patients with autoimmune disorders who received CYC for >3 months, five developed bladder cancers.<sup>54</sup> A long-term follow-up of 119 patients with rheumatoid arthritis (RA) identified nine bladder cancers.<sup>52</sup> In seven of nine patients with bladder cancer, the total cumulative dose of CYC exceeded 80 g.<sup>52</sup> These various studies underscore the importance of limiting the total cumulative dose of CYC. Bladder complications are less frequent with pulse IV CYC.<sup>8</sup>

Newer therapeutic regimens aimed at reducing the total dose of CYC by using alternative immunosuppressants appear to have a significant benefit with regard to risk of bladder complications. In a single-center, retrospective study using a strategy that avoided or limited CYC with either initial treatment with MTX or rapid transition to MTX after 3 to 6 months of CYC, no cases of hemorrhagic cystitis or bladder cancer were reported in 253 patients with a median follow-up period of 4.5 years.<sup>8</sup> Patients in this series were treated with daily oral CYC of 2 mg/kg, and MTX was continued for at least a 2-year period.<sup>8</sup>

### Induction of Other Malignant Neoplasms

CYC has been associated with an increased risk of carcinomas of the skin,<sup>50,55</sup> female genital tract (predominantly cervical atypia),<sup>56</sup> and malignant lymphoproliferative disorders.<sup>3,30,38,39,51</sup> The risk of neoplasia associated with CYC is dose dependent. Malignancies may develop 5 to 15 years after initiation of therapy.<sup>49,50,52,55</sup> A prior history of malignancy or tobacco use increases the risk.<sup>50,52</sup> Leukemias, lymphoma, and myelodysplastic syndromes are the most dreaded complications and may be refractory to therapy.<sup>3,30,38,39</sup> In a sentinel study of patients with non-Hodgkin lymphoma treated with alkylating agents, the risk of developing leukemias was 1.5% per year up to 9 years.<sup>38</sup> Subsequent studies in autoimmune and inflammatory disorders affirmed an increased risk of hematologic malignancies with chronic CYC therapy.<sup>50,55</sup> In a retrospective long-term study of patients with WG treated with CYC, the incidence of malignancy was increased for squamous cell carcinoma of the skin [odds ratio (OR)=7.3], leukemias (OR=5.7), and malignant lymphomas (OR=4.2).<sup>57</sup> In another retrospective series of WG patients, the risk of malignancies was not increased for patients treated with cumulative CYC doses of ≤36 g, but

there was an elevated risk of nonmelanoma skin cancers and a markedly elevated risk of acute myelogenous leukemia (AML) (59-fold increase in standardized incidence ratio) in those receiving a cumulative dose of  $\geq 36$  g.<sup>39</sup> By contrast, in a Swedish registry of scleroderma patients, the risk of malignancy was no higher in 246 patients treated with CYC compared with those treated with other medications.<sup>58</sup> The risk of malignancy is influenced by underlying disease and concomitant medications,<sup>28</sup> with a higher risk of solid tumors seen in one study of WG patients treated with the combination of CYC and etanercept.<sup>59</sup>

### Gonadal Toxicity and Teratogenicity

Ovarian failure results from direct toxicity to the granulosa cell.<sup>30</sup> Ovarian failure is dose and age dependent and occurs with both oral and IV CYC.<sup>3,30,60</sup> In breast cancer patients, mean cumulative dosages of CYC resulting in ovarian failure in women in their twenties, thirties, or forties were 20, 9, and 5 g, respectively.<sup>60</sup> Oral contraceptives<sup>61</sup> or gonadotropin hormone-releasing analogues (eg, depot-leuprolide acetate)<sup>62</sup> may confer protection against ovarian fibrosis, and oocyte or embryo cryopreservation can also be considered. CYC is a potent teratogen; even a single dose during pregnancy can result in severe deformities.<sup>63</sup> Reliable contraceptive techniques should be employed during and 6 months after treatment with CYC. Azoospermia occurs in men<sup>64</sup> with the risk of irreversible infertility, and sperm banking should be considered. Testosterone supplementation during CYC may preserve testicular function in men.<sup>29,65</sup>

### Miscellaneous Adverse Effects

Rarely, hyponatremia has been noted with IV pulse CYC if excessive water is administered intravenously.<sup>30</sup> Diffuse myocardial damage complicating CYC use has been described,<sup>28,66</sup> but is rare.

### MONITORING

CYC exhibits bone-marrow suppressive effects.<sup>28</sup> With either oral or IV pulse CYC, complete blood counts (CBCs) and platelet counts should be obtained within 1 to 2 weeks of initiation of therapy. With oral CYC, CBCs should be obtained every 2 weeks for the first 6 weeks. Once a stable dose has been achieved, CBC at 4- to 6-week intervals is usually adequate. The oral dose should be reduced if total leukocyte count falls below  $3000 \text{ mm}^3$ . With IV CYC, CBCs are obtained on days 0, 7, and 14. The dose is adjusted to maintain total leukocyte count nadir  $>2000 \text{ mm}^3$ . In cases of severe granulocytopenia, granulocyte colony-stimulating factor (G-CSF) may accelerate recovery. Refractory pan-

cytopenias may warrant bone marrow biopsy with karyotyping to rule out myelodysplastic syndrome or malignancy.<sup>39</sup>

Because of potential bladder toxicity, urinalysis should be performed at least every 3 months during CYC therapy. Nonglomerular hematuria (microscopic or macroscopic) is a marker of CYC-induced bladder injury and warrants cystoscopy to exclude bladder carcinoma.<sup>49</sup> Patients with a history of hemorrhagic cystitis (even without cellular atypia) are at increased risk for bladder cancer; thus, in this context, we recommend urinalysis every 3 to 6 months and urine cytologies every 6 to 12 months even after CYC has been discontinued. Consideration should also be made for routine cystoscopy monitoring every 1 to 2 years in these patients.<sup>67</sup> For patients with no history of CYC-induced hemorrhagic cystitis, serial urinalyses are adequate for bladder cancer surveillance.

Age-appropriate cancer screening is also recommended, including annual Pap smears, and periodic assessment of liver function tests (LFTs) should be performed to rule out hepatotoxicity.<sup>29</sup>

### CHLORAMBUCIL

Chlorambucil, an alkylating agent related to CYC,<sup>30</sup> was used to treat WG in early studies, with anecdotal successes,<sup>68,69</sup> but is oncogenic and has myriad toxicities.<sup>29,30</sup> Currently, chlorambucil has no role to treat vasculitis.

### METHOTREXATE

MTX has regulatory approval to treat RA, psoriasis, and several malignancies<sup>28,70</sup> and has been used to treat diverse autoimmune and inflammatory disorders, including AAV.<sup>30,70</sup> MTX can be used as (1) *induction* therapy for patients with mild to moderate (non-life-threatening) AAV,<sup>7,71,72</sup> (2) *maintenance* therapy for patients who have achieved CRs after initial treatment with CYC,<sup>5-8,72-74</sup> and (3) *induction or salvage therapy* for patients experiencing adverse effects from CYC.<sup>8,75</sup>

### Mechanism of Action

MTX (N-10-methyl-aminopterin) impairs folate synthesis via competitive inhibition of dihydrofolate reductase, resulting in impaired thymidylate and DNA synthesis.<sup>70,76</sup> MTX has antiinflammatory and immunomodulatory effects without substantial effects on cell numbers.<sup>70,76</sup> MTX inhibits neutrophil recruitment and responses to inflammatory mediators, neutrophil adherence to endothelial cells, neutrophil and monocyte chemotaxis, production or activation of numerous inflammatory cytokines (including TNF- $\alpha$  and interleukin-1), and B cell differentiation.<sup>29,70,76</sup>

### Dosage, Route of Administration, Pharmacology

MTX can be administered orally or intramuscularly (dose range of 15 to 25 mg once weekly).<sup>7,8,75,77</sup> Both routes are comparable in efficacy, but parenteral administration is recommended for patients with gastrointestinal (GI) toxicity with oral MTX or under conditions of reduced oral bioavailability.<sup>70,76</sup> We initiate therapy with an oral dose of 7.5 mg, with dose increases by 2.5 mg weekly up to 15 mg once weekly. Higher doses may be needed for disease poorly controlled at lower doses. The kidneys are the major route of MTX elimination, and toxicity is increased in the presence of renal insufficiency.<sup>30</sup> Conditions that may increase toxicity include hypoalbuminemia; concomitant drugs that affect absorption, clearance, or protein binding of MTX; and folate deficiency.<sup>30</sup> Acute renal failure, serum creatinine >2.0 mg%, or chronic liver disease are contraindications to MTX use.<sup>8,72</sup> The concomitant use of MTX and T/S 160 mg/800 mg twice daily may cause severe pancytopenia.<sup>75</sup> However, we believe low-dose T/S (80/400) thrice weekly can safely be used for prophylaxis against PCP, although this is controversial.

### Toxicity

MTX has myriad potential toxicities, but it lacks bladder toxicity and is not oncogenic.<sup>29,30,78</sup> Adverse effects are dose dependent; drug discontinuation is necessary in 3% to >15% of patients due to side effects.<sup>30,78</sup> Life-threatening side effects are rare (<2%).<sup>30,78</sup> British investigators evaluated 673 patients treated with MTX for diverse rheumatologic disorders; side effects led to discontinuation of therapy in 36.3%.<sup>78</sup> Reasons for discontinuing therapy were GI symptoms (10.8%), abnormal LFTs (5.5%), peripheral blood cytopenias (5.5%), pulmonary symptoms (3%), and cutaneous abnormalities (2.1%). Concomitant administration of folic acid 1 mg/day attenuates toxicity, especially nausea and cytopenias, without reducing efficacy.<sup>37,79,80</sup>

### Bone Marrow

Megaloblastic anemia, leukopenia, or thrombocytopenia complicates MTX use in 1 to 5% of patients, but severe bone marrow suppression is rare.<sup>30,70,81</sup> Hematologic complications are more common in patients with renal dysfunction, advanced age, decreased serum albumin, preexisting anemia or macrocytosis, dehydration, or concomitant administration of nonsteroidal antiinflammatory drugs (NSAIDs).<sup>30,70,81</sup> The use of T/S may potentiate bone marrow toxicity,<sup>82</sup> but this effect is usually minor.<sup>70</sup> Increases in mean corpuscular volume (MCV) or decreases in hemoglobin, leukocyte, or platelet counts should prompt temporary cessation of

MTX.<sup>30</sup> We advocate supplemental folic acid 1 mg/day to reduce toxicity.

### Gastrointestinal

GI symptoms (eg, nausea, anorexia, vomiting, diarrhea) are the most common adverse effects associated with MTX, noted in 10 to 40% of patients.<sup>30,70,78</sup> Rarely, severe mucositis involving the GI tract can cause bleeding or pain. Minor GI adverse effects are often resolved by reducing the oral dose or converting to the intramuscular route with withdrawal of therapy occurring in only ~10% of patients.<sup>29,30,70,78</sup> Parenteral administration bypasses the liver, with consequent diminution in hepatic synthesis of 7-hydroxy MTX, the main metabolite of MTX.<sup>30</sup>

### Hepatic Toxicity

The most serious complication of MTX is hepatotoxicity and the development of hepatic steatosis and/or fibrosis.<sup>70,78,83</sup> Early studies of daily MTX therapy for psoriasis showed a high rate of progression to cirrhosis (3 to 10%).<sup>70,84</sup> Subsequent studies in RA and other inflammatory disorders cited a low risk of severe hepatotoxicity with once-weekly MTX in the absence of risk factors.<sup>30,70,85-87</sup> Factors associated with an increased risk of hepatotoxicity include preexisting liver disease, diabetes mellitus, excessive alcohol use, obesity, advanced age, concomitant use of NSAIDs, and renal insufficiency.<sup>30,87</sup> Several studies in RA patients receiving MTX found that severe liver disease or cirrhosis was rare (<0.5%).<sup>28,30,83,87</sup> In the setting of AAV, MTX use was associated with liver dysfunction in 5 to 14% of cases.<sup>71,88</sup> The American College of Rheumatology no longer recommends *routine* surveillance liver biopsies even in RA patients taking MTX for prolonged periods (>5 years).<sup>87</sup> However, routine monitoring of transaminases should be performed every 4 to 8 weeks throughout therapy. Liver biopsy should be considered for patients with sustained elevations of transaminases (>2 to 3 times normal) or with suspected liver disease.<sup>30</sup>

### Pulmonary

Pulmonary toxicity occurs in 2 to 7% of patients on chronic MTX therapy.<sup>29,30,89,90</sup> Clinical features include dyspnea, cough, and pulmonary infiltrates; in some patients, fever and constitutional symptoms may mimic pneumonia.<sup>30,89</sup> Bronchoalveolar lavage (BAL) may reveal lymphocytosis and increased CD8:CD4 ratio.<sup>91</sup> Histological features of MTX pneumonitis are diverse and include nonspecific interstitial inflammatory cell infiltrates, granulomata, giant cells, bronchiolitis, and fibrosis.<sup>30,89</sup> The risk of MTX is not affected by gender, smoking, or duration of therapy.<sup>30,89,90</sup> One study in RA

patients found older age, diabetes, rheumatoid pleuro-pulmonary involvement, previous use of disease-modifying antirheumatic drugs (DMARDs), and hypoalbuminemia to be risk factors for the development of MTX-induced lung injury.<sup>92</sup> Most cases develop within the first year of MTX therapy, but pneumonitis can develop >3 years after chronic MTX therapy.<sup>30,89,90</sup> Routine high-resolution computed tomographic (CT) scans or PFTs do not predict which patients may develop pulmonary toxicity.<sup>93</sup> High-dose CSs may accelerate resolution and are recommended in severe or fulminant cases.<sup>30,90</sup> Rechallenge with MTX is dangerous with a high rate of recurrence and is thus ill advised.<sup>30,94</sup> The reported fatality associated with MTX-associated lung injury is ~17%.<sup>94</sup> Airway hyperresponsiveness has also been described with MTX<sup>95</sup> and may mimic asthma.

### Infections

As with all immunosuppressive agents, MTX increases the risk of bacterial, viral, and opportunistic infections.<sup>29,30,96,97</sup> The risk is low among patients receiving monotherapy with MTX but is increased when concomitant CSs or other immunosuppressive agents are utilized.<sup>30,96</sup> In a review of 25 opportunistic infections complicating chronic MTX therapy, PCP was implicated in 10 (40%).<sup>96</sup>

### Induction of Neoplasia

MTX may cause chromosomal breaks<sup>98</sup> but has no direct oncogenic effect.<sup>30,98,99</sup> Anecdotal reports of malignant lymphoproliferative disorders in patients with RA and dermatomyositis reflect Epstein-Barr virus (EBV) replication due to defective immune surveillance.<sup>100–102</sup> In a cohort of >16,000 RA patients receiving disease-modifying drugs, 39 developed hematologic malignancies (12 of whom had received MTX).<sup>98</sup> Malignancies in MTX-treated patients included nine lymphomas and three acute leukemias or myelodysplastic syndromes. Analysis of the oncogenic risk is complicated because the 12 MTX-treated patients developing malignancy had received a mean of 3.3 disease-modifying drugs. No correlations were observed between the dose or duration of MTX and development of malignancy.<sup>98</sup> Thus existing data do not clearly support a relationship between MTX use and hematologic malignancies. Interestingly, spontaneous regression of lymphomas (more commonly EBV-positive) has been reported after withdrawal of MTX therapy in both RA and transplant patients.<sup>29</sup>

### Gonadal Toxicity and Teratogenesis

MTX is teratogenic and may induce abortion.<sup>30,103</sup> In animals, embryonic exposure to MTX may stunt fetal growth and cause birth defects (principally anomalies of

the central nervous system or palate). Data in humans are limited, but exposure to MTX in the first trimester has been associated with multiple fetal anomalies.<sup>30,103</sup> MTX should not be used in women of childbearing age unless adequate birth control measures are utilized.<sup>104,105</sup> Conception should not be attempted if either partner has been exposed to the drug within 6 months. MTX is excreted in breast milk in small quantities<sup>30</sup>; breast-feeding during maternal use of MTX is not recommended. Oligospermia (typically reversible) and impotence in men<sup>106</sup> and amenorrhea in women<sup>30</sup> have rarely been described following MTX use.

### Miscellaneous Adverse Effects

Other adverse effects of MTX include stomatitis (manifesting as painful oral ulcers), in 2 to 8%; cutaneous reactions (eg, vasculitis, rash, urticaria), in 2 to 6%; and alopecia in 1 to 5%.<sup>30,70,81</sup> Although MTX does not cross the blood-brain barrier, headache, dizziness, cognitive impairment, and dysphoria may complicate its use.<sup>28,30,70</sup> High-dose MTX may cause encephalomalacia.<sup>30</sup> Renal insufficiency can result from precipitation of MTX in the kidney, particularly in patients with preexisting renal insufficiency.<sup>30,70</sup>

### MONITORING

Because of potential bone marrow and hepatic toxicity, we obtain CBCs, platelet counts, and LFTs within 4 weeks of initiation of therapy, and every 4 weeks for the first 3 months. Once a stable dose has been achieved, CBC and LFTs every 6 to 8 weeks is usually adequate.

### AZATHIOPRINE

AZA has been used to prevent allograft rejection in organ transplant recipients and has a role as a steroid-sparing agent in diverse autoimmune and inflammatory disorders.<sup>28–30</sup> AZA is less effective than CYC and should *not* be used as *primary* therapy for AAV<sup>2,107,108</sup> but may be used as *maintenance* therapy in patients who remit with CYC and CSs.<sup>4,6</sup> In a prospective, open-label, multicenter trial, AZA was as effective as MTX *as maintenance therapy* for AAV.<sup>6</sup> The decision about whether to use MTX or AZA for remission maintenance must be made on an individual patient basis. Though it is not standard practice, anecdotal case reports cited remissions with IV pulse AZA for active refractory WG.<sup>109</sup> Given the availability of other therapeutic options, we do not recommend this approach.

### Mechanism of Action

AZA, a purine analogue, inhibits DNA synthesis of proliferating cells and has minor inhibitory effects on

RNA and protein synthesis.<sup>28,30</sup> The drug is inactive as administered but is metabolized intracellularly to the purine antagonists 6-mercaptopurine (6-MP) and 6-thioinosinic acid.<sup>30</sup> AZA suppresses both humoral and cellular immunity.<sup>30</sup> It also induces lymphopenia, reduces T and B cell numbers, suppresses antibody synthesis, and depletes natural killer (NK) cells.<sup>30</sup> AZA is less potent than CYC and exerts its immunosuppressive effects more slowly, often over weeks or months.

### **Dosage, Route of Administration, Pharmacology**

AZA is administered orally (dose 1 to 3 mg/kg/day).<sup>30</sup> An IV formulation has been developed and rarely used in pulse dosing (1200 to 1800 mg IV monthly), but data are limited, and we do not recommend parenteral administration. AZA is cleared by renal excretion and metabolic degradation.<sup>30</sup> Mercaptopurine (6-MP) is metabolized by the enzyme thiopurine methyltransferase (TPMT) to thiopurine analogues. Deficiency of this enzyme, secondary to a homozygous mutation for TPMT, occurs in one in 300 individuals<sup>28</sup> and may lead to increased toxicity.<sup>110</sup> Some investigators advise measuring TPMT activity before initiating AZA,<sup>110</sup> but we do not believe this practice is cost-effective. We initiate AZA at low dose (50 mg) and monitor clinically (symptoms, blood tests) for toxicity. Barring adverse effects, the dose can be increased every 2 weeks by 50 mg (maximum dose of 200 mg daily). Allopurinol inhibits the metabolism of 6-MP to 6-thiouric acid, thereby increasing the toxicity of AZA.<sup>28</sup> In patients receiving AZA, the doses of AZA and allopurinol should be reduced to one third the standard dose.<sup>30</sup>

### **Toxicity**

AZA has myriad potential toxicities (principally bone marrow suppression,<sup>111</sup> heightened susceptibility to infections, and GI toxicities), but it lacks bladder toxicity and has low oncogenic potential.<sup>29,30</sup>

### **Bone Marrow Suppression**

AZA has dose-dependent inhibitory effects on bone marrow; all cell lines are affected.<sup>111,112</sup> Severe toxicity is rare provided dose adjustments are made in response to peripheral blood counts. In 739 patients with inflammatory bowel disease (IBD) treated with AZA for a mean of 12.5 months, leukopenia developed in 28 (3.7%) and thrombocytopenia in 2.0%.<sup>112</sup> In a cohort of 393 patients with RA, AZA was associated with four episodes of leukopenia per 100 patient-years.<sup>113</sup> Chronic administration may result in anemia and thrombocytopenia.<sup>30</sup> Megaloblastosis may herald bone marrow toxicity.<sup>30</sup> In some cases, the onset of pancytopenia is abrupt; pure red

cell aplasia has been described.<sup>30</sup> Bone marrow toxicity reverses with reducing the dose or discontinuing therapy. The risk of toxicity is increased in patients deficient in the enzyme TPMT, and severe myelosuppression can be seen in this setting.<sup>114</sup> The concurrent use of allopurinol and AZA also greatly enhances the hematologic toxicity.<sup>37</sup>

### **Gastrointestinal Toxicity**

Nausea is common but rarely severe enough to warrant discontinuation of therapy.<sup>30,112</sup> Pancreatitis complicates the use of AZA or 6-MP in up to 3.3% of patients.<sup>112</sup> This usually occurs within the first month of therapy and promptly resolves following cessation of AZA.<sup>112</sup> Severe hepatotoxicity is rare (0.3%) but is more common in patients who are TPMT deficient.<sup>112,115-117</sup> Hepatitis and cholestatic jaundice usually reverse with drug cessation,<sup>112</sup> but venoocclusive disease is usually irreversible.<sup>115,116</sup> We obtain LFTs at 2 and 4 weeks from initiation of AZA, and thereafter at 4- to 8-week intervals.

### **Pulmonary Toxicity**

AZA is not considered a pulmonary toxin, but a single case of AZA-induced pulmonary hemorrhage was reported in a child following renal transplantation.<sup>118</sup>

### **Infections**

As with all immunosuppressive agents, AZA increases the risk of bacterial, viral, and opportunistic infections.<sup>29,30,112</sup>

### **Induction of Neoplasia**

The oncogenic potential associated with AZA is controversial. AZA has been associated with an increased risk of cutaneous<sup>119</sup> and cervical carcinomas<sup>56,120</sup> and lymphoproliferative disorders.<sup>54,121-123</sup> The risk of malignancy varies considerably according to the underlying disease. The risk of cutaneous squamous cell carcinoma was increased in RA and other immune disorders receiving AZA. Further, the course of cutaneous squamous cell carcinomas may be more aggressive in patients receiving AZA.<sup>119</sup> The incidence of hematological malignancies is increased up to 60-fold among organ transplant recipients receiving AZA combined with other immunosuppressive agents.<sup>121</sup> The risk of neoplasia is much lower among patients with autoimmune disease receiving AZA.<sup>124</sup> The risk of non-Hodgkin lymphoma was increased in patients receiving AZA for RA<sup>54</sup> or chronic liver disease.<sup>123</sup> In contrast, only one lymphoma was observed in more than 1100 patients with IBD treated with AZA or 6-MP in three series.<sup>54,112,125</sup> In

a cohort of 207 patients with multiple sclerosis treated for a mean of 4.2 years with AZA, five malignancies were identified compared with seven in a control group.<sup>126</sup> In a study of AZA in AAV, treatment for more than 12 months was associated with an all cancer standardized mortality rate of 3.0, though the majority of cases were skin carcinomas.<sup>127</sup> These data suggest that the oncogenic risk of AZA is overall low and depends upon the underlying disease(s).<sup>29,30</sup>

### Gonadal Toxicity and Teratogenesis

AZA is teratogenic in animals<sup>128</sup> and is listed as a pregnancy category D drug, though its effects on fetal development in humans have not been clearly elucidated. However, AZA is safer than alkylating agents or MTX. The rate of fetal anomalies among women receiving AZA during pregnancy approximates 3%.<sup>63,129</sup> Maternal use of AZA has been associated with an increased risk of spontaneous abortions, prematurity, congenital malformations, and low birth weight as well as neonatal leukopenia or pancytopenia.<sup>29,130</sup> Most reports of adverse effects have occurred in woman taking concomitant drugs or with comorbidities.<sup>63,129</sup> We do not believe termination of pregnancy is warranted when women become pregnant while taking AZA. AZA does not cause permanent gonadal toxicity or sterility.<sup>30</sup> AZA is excreted in breast milk<sup>129</sup>; breast feeding while receiving AZA is not advised.

### Miscellaneous Adverse Effects

An idiosyncratic hypersensitivity syndrome with fevers, rash, and arthralgias occurs in 2% of patients receiving AZA. These reverse with cessation of exposure and may recur with reexposure.<sup>30</sup> Other adverse effects of AZA include alopecia, stomatitis, and muscle weakness.<sup>28</sup>

### MONITORING

Because of potential bone marrow and hepatic toxicity, we obtain CBCs, platelet counts, and LFTs within 2 weeks of initiation of therapy, and every 2 weeks for the first 6 weeks. Once a stable dose has been achieved, CBC and LFTs at 4- to 8-week intervals is usually adequate. We do not monitor therapy according to TMTP.

### MYCOPHENOLATE MOFETIL

MMF has regulatory approval for prophylaxis of organ allograft rejection in cardiac, liver, and renal transplant recipients and has been used to treat diverse autoimmune and inflammatory disorders.<sup>28,29</sup> Mycophenolate has been used to induce or maintain remissions in AAV (principally WG),<sup>131-134</sup> but data are limited. Studies comparing MMF with other agents for AAV are lacking. However, MMF is at least as effective as AZA

for the treatment of systemic lupus erythematosus,<sup>135,136</sup> and for prevention of rejection in transplant recipients.<sup>137-140</sup> In AAV (principally WG), small trials and observational studies cited successful remission induction and remission maintenance with MMF.<sup>131-134,141</sup> Only a single randomized, controlled trial compared the efficacy of MMF with AZA for AAV remission maintenance. In this trial, MMF was less effective than AZA for maintaining disease remission, and both treatments had similar adverse event rates.<sup>142</sup> Higher MMF dosing may improve its efficacy, but the doses used in this study were similar to or greater than doses previously reported for remission maintenance in AAV.<sup>131-133</sup> Based on this study, MMF should *not* be considered first-line therapy for remission maintenance in AAV, although it may still be considered for refractory cases.

### Mechanism of Action

Following administration, MMF is rapidly converted to the active metabolite mycophenolic acid (MPA). MPA is a reversible, noncompetitive inhibitor of inoside monophosphate dehydrogenase, a critical enzyme in de novo purine synthesis.<sup>143</sup> Lymphocytic proliferation relies almost exclusively on de novo purine synthesis, whereas most other cell types can utilize the salvage pathway as well. MMF inhibits T- and B-lymphocyte proliferation, induces apoptosis of activated T-lymphocytes, and suppresses primary antibody responses and expression of vascular adhesion molecules.<sup>29,143</sup>

### Dosage, Route of Administration, Pharmacology

MMF is administered orally, typically with a daily dose of 1500 to 3000 mg in two divided doses.<sup>29</sup> African Americans metabolize MMF more rapidly than Caucasians and may require larger doses. Renal insufficiency may increase toxicity, and lower doses should be used in renal failure.<sup>29</sup> Mycophenolate sodium (Myfortic, Novartis Pharmaceuticals Corp., Hanover, NJ), a delayed release enteric formulation of MMF,<sup>28</sup> may be substituted for MMF in patients that exhibit poor tolerance of MMF (principally GI toxicities).

### Toxicity

The most common reported toxicities of MMF include infections and gastrointestinal toxicity, but it may be better tolerated than alternative therapies. In a randomized, controlled trial of MMF versus AZA versus IV bolus CYC after induction of remission of lupus nephritis, the MMF group had a lower rate of hospitalizations, amenorrhea, infections, nausea, and vomiting.<sup>144</sup>



### Bone Marrow Suppression

Because other cell types (nonlymphocytic) can use salvage pathways for purine synthesis,<sup>28</sup> MMF has less suppressive effects on bone marrow cell lines than CYC or AZA.<sup>29</sup> However, neutropenia can complicate its use and may require dose reduction.<sup>28,145</sup>

### Gastrointestinal

GI adverse effects including nausea, vomiting, diarrhea, and abdominal pain are common in MMF-treated patients but may get better with time and usually do not require cessation of the drug.<sup>29</sup> For some patients, GI symptoms improve with more frequent dosing intervals maintaining the same total daily dose. Enteric-coated mycophenolate sodium (EC-MPS) was developed with the aim of improving the GI tolerability of mycophenolic acid. The few trials comparing EC-MPS with MPS have not shown a significant impact in the incidence of GI adverse events.<sup>146,147</sup> However, in a prospective, open-label trial, conversion from MMF to EC-MPS significantly reduced GI-related symptoms.<sup>148</sup>

### Pulmonary

Dyspnea and cough are reported in the MMF prescribing information, but at similar rates to AZA and are probably related to respiratory infections.<sup>29</sup>

### Infections

Consistent with other immunosuppressive agents, MMF is associated with heightened susceptibility to infections.<sup>29,144</sup> Although it is somewhat counterintuitive, MMF is reported to have some protective antimicrobial activity against intracellular pathogens, including PCP.<sup>149,150</sup> Regardless, for patients treated with MMF in conjunction with CSs, we recommend prophylaxis against PCP.

### Induction of Neoplasia

MMF prescribing information includes a specific warning about lymphoma and other neoplasms as a result of immunosuppression, but the oncogenic potential of MMF is generally considered to be less than with CYC. However, the long-term risk of hematologic malignancy is unknown.

### Gonadal Toxicity and Teratogenesis

Data regarding effects of MMF during pregnancy are scant. Teratogenicity has been cited in animals, but data in humans are limited.<sup>29</sup> MMF is pregnancy category C.<sup>29</sup> Contraception should be used in any patient taking MMF.

### MONITORING

Serum MMF levels are unpredictable and highly variable,<sup>151</sup> and monitoring drug levels is cumbersome.<sup>151–153</sup> Given the uncertain benefit, we do not recommend monitoring drug levels. However, because of potential for bone-marrow toxicity, we obtain a CBC within 2 weeks of initiation of therapy, and every 2 weeks for the first 6 weeks. Once a stable dose has been achieved, repeating the CBC every 4 to 8 weeks is usually adequate.

### TUMOR NECROSIS FACTOR INHIBITORS

Inhibitors of TNF- $\alpha$  have been used to treat active RA, psoriasis,<sup>154</sup> IBD,<sup>155–157</sup> ankylosing spondylitis (AS),<sup>158</sup> and diverse autoimmune and inflammatory disorders.<sup>159–162</sup> TNF- $\alpha$  antagonists most commonly used include etanercept (Enbrel, Immunex Corp., Thousand Oaks, CA), infliximab (Remicade, Centocor Ortho Biotech, Inc., Horsham, PA), and adalimumab (Humira, Abbott Laboratories, Rockville, MD)<sup>157,160,162</sup>; two newer agents, golimumab and certolimumab, are now available<sup>161</sup> but will not be further discussed here. The monoclonal antibodies infliximab and adalimumab are approved as therapy for active RA, juvenile RA, psoriatic arthritis, plaque psoriasis, AS, and IBD.<sup>161,162</sup> Etanercept is not effective to treat IBD but appears to be as effective as the preceding monoclonal antibodies to treat RA, psoriasis, and AS.<sup>161,162</sup> Data regarding the use of TNF- $\alpha$  inhibitors for vasculitis are limited (discussed elsewhere in this issue by Lynch and Tazelaar). TNF- $\alpha$  inhibitors have been used to treat giant cell vasculitis,<sup>163,164</sup> Behçet disease,<sup>165,166</sup> Churg-Strauss syndrome,<sup>167</sup> WG,<sup>159</sup> and AAV,<sup>15,16,168–170</sup> with anecdotal successes (particularly with infliximab). The Wegener Granulomatosis Etanercept Trial (WGET) randomized 180 patients with WG to etanercept or placebo in addition to standard therapy with CYC or MTX.<sup>170</sup> Patients were followed for a minimum of 12 months. Etanercept was no better than placebo. Based on this study, etanercept has no role as therapy for WG. Conversely, infliximab may be effective as induction therapy or treatment of refractory AAV. Five clinical trials<sup>16,171–174</sup> and anecdotal case reports<sup>175–177</sup> suggest a possible role for infliximab in refractory WG (discussed in greater detail in this issue by Lynch and Tazelaar). We are unaware of data assessing adalimumab as therapy for AAV. Placebo-controlled trials are necessary to ascertain the role of infliximab or other TNF- $\alpha$  inhibitors for AAV.

### Mechanism of Action

Etanercept, a dimeric fusion protein composed of two p75 TNF- $\alpha$  receptors coupled to the Fc portion of a monoclonal human IgG<sub>1</sub>, binds TNF- $\alpha$  in a one-to-one

fashion.<sup>169</sup> Infliximab, a chimeric mouse/human monoclonal antibody, binds to either membrane-bound or soluble TNF- $\alpha$ .<sup>16</sup> Blockage of TNF- $\alpha$  leads to inhibition of proinflammatory cytokines with potent antiinflammatory and antifibrotic effects.<sup>160</sup>

### Dosage, Route of Administration, Pharmacology

Etanercept is administered subcutaneously (dose 25 to 50 mg twice weekly for 3 months, then once weekly). The dose of infliximab for RA and IBD has typically been 5 mg/kg body weight, administered via IV infusion at day 0, 2 weeks, 6 weeks, and thereafter every 8 weeks.<sup>160-162</sup> However, dose (range 3 to 10 mg/kg), frequency of dosing, and duration of therapy have varied in published series of autoimmune disorders and AAV.<sup>160,162,173</sup> Adalimumab is administered subcutaneously (dose 40 mg every 2 weeks) for most indications.<sup>160</sup> The optimal regimen for AAV (dose, frequency of administration, duration of therapy) has not been elucidated.

### Toxicity

Major toxicities of TNF- $\alpha$  inhibitors include opportunistic infections,<sup>178,179</sup> heightened risk of malignancy,<sup>179,180</sup> induction of autoimmune antibodies and lupus-like syndromes,<sup>181</sup> and infusion or injection site reaction.<sup>159</sup> In contrast to immunosuppressive cytotoxic agents, bone marrow toxicity is rare.

### Bone Marrow Suppression

Leukopenia, anemia, and thrombocytopenia rarely complicate the use of TNF- $\alpha$  inhibitors. The mechanism is not clear.<sup>159</sup>

### Gastrointestinal Toxicity

GI adverse effects are uncommon. However, elevated transaminases, and rarely severe autoimmune hepatitis have been cited with TNF- $\alpha$  inhibitors.

### Pulmonary Toxicity

The effect of TNF- $\alpha$  inhibitors on causing or modifying the course of lung disease is not clear.<sup>182</sup> TNF- $\alpha$  inhibitors have been used to treat diverse interstitial lung diseases (ILDs), such as sarcoidosis,<sup>183-188</sup> idiopathic pulmonary fibrosis,<sup>189</sup> and connective tissue disease-associated ILD,<sup>181,190,191</sup> but efficacy has not been convincing. Further, several case reports and small series cited either rapid progression of RA-associated ILD or new development of ILD following initiation of anti-TNF- $\alpha$  therapy.<sup>181,192-196</sup> However, this could reflect

exacerbation of the underlying disease rather than a direct toxic effect of TNF- $\alpha$  inhibitors. A recent prospective study identified 367 patients with preexisting RA-ILD (299 were treated with TNF- $\alpha$  agents; 68, with DMARDs).<sup>182</sup> Mortality was no higher in patients receiving TNF- $\alpha$  inhibitors compared with DMARDs.

### Infections

Serious opportunistic infections (ie, bacterial,<sup>197</sup> tuberculosis<sup>178,198</sup> or nontuberculous mycobacterial,<sup>158</sup> viral (particularly herpes zoster)<sup>199</sup> and cytomegalovirus (CMV),<sup>156,166</sup> hepatitis B reactivation,<sup>200</sup> PCP,<sup>201</sup> aspergillosis,<sup>202,203</sup> coccidioidomycosis,<sup>158</sup> cryptococcosis,<sup>204</sup> histoplasmosis,<sup>205</sup> listeriosis,<sup>206</sup> nocardiosis,<sup>158</sup> and other opportunistic infections have been associated with therapy with TNF- $\alpha$  antagonists.<sup>178,179,207,208</sup> In virtually all these reports, CSs or immunosuppressive agents were used concomitantly, confounding interpretation of the impact of TNF- $\alpha$  inhibitors. Data collected from the U.S. Food and Drug Administration (FDA) from January 1998 to September 2002 cited 716 granulomatous infections associated with the use of either etanercept or infliximab.<sup>158</sup> Data extracted from >346,000 U.S. patients treated over a 4.75-year period identified 374 reported cases of tuberculosis, 42 of histoplasmosis, and 223 with other granulomatous infections.<sup>158</sup> Overall, the rate of infections were 239 per 100,000 infliximab-treated patients compared with 74 per 100,000 etanercept-treated patients (<0.001). Tuberculosis was the most commonly reported granulomatous infection, cited in 144 per 100,000 infliximab-treated patients and in 35 per 100,000 etanercept-treated (<0.001).<sup>158</sup> Other granulomatous infections were also more common among patients receiving infliximab. Importantly, 208 infections occurred *without* concomitant use of immunosuppressive medications; of these, 189 were associated with infliximab and 19 with etanercept treatment. The median time to onset of infection was 40 days for infliximab and 236 days for etanercept (<0.001). In summary, infliximab was associated with a more than threefold risk of infections compared with etanercept, and infections occurred shortly after initiation of therapy. The time-frame suggests that most infections in infliximab-treated patients represented reactivation of latent infection. Data regarding adalimumab were not available in that report. Both infliximab and adalimumab carry a "black box" warning about the risk of tuberculosis and other opportunistic infections. Testing for latent tuberculosis [ie, tuberculin skin test (PPD) or TB-quantiferon-GOLD] should be performed in all patients before initiation of anti-TNF- $\alpha$  therapy. Patients with latent tuberculosis should be treated before initiation of anti-TNF- $\alpha$  therapy. A prospective study in the United Kingdom examined serious infection rates between 2002 and 2005 in a large

cohort of RA patients receiving TNF- $\alpha$  antagonists ( $n=7664$ ) or conventional DMARD ( $n=1354$ ).<sup>178</sup> There were 525 infections in the anti-TNF- $\alpha$  cohort, compared with 56 in the DMARD cohort. The overall incidence of infection, adjusted for baseline risk, was similar in both cohorts. However, the frequency of serious skin and soft tissue infections was increased in anti-TNF- $\alpha$  treated patients, with an adjusted incidence rate ratio (IRR) of 4.28. Further, all 19 bacterial intracellular infections [ie, *M. tuberculosis* ( $n=10$ ), *Listeria monocytogenes* ( $n=3$ ), other ( $n=6$ )] occurred in the anti-TNF- $\alpha$  cohort. There was no difference between the three TNF- $\alpha$  antagonists (infliximab, adalimumab, or etanercept). German investigators prospectively studied 5040 RA patients receiving TNF- $\alpha$  inhibitors or DMARDs.<sup>199</sup> Eight-six herpes zoster infections were documented in 82 patients. The crude incidence per 1000 patient years was 11.1 for the monoclonal antibodies (infliximab or adalimumab), 8.9 for etanercept, and 5.6 for conventional DMARDs.

### Induction of Neoplasia

Malignancies (solid and hematological) may complicate use of TNF- $\alpha$  antagonists, but the actual risk depends upon underlying disease(s), concurrent immunosuppressive or cytotoxic drug therapy, and preexisting history of malignancy, among other factors.<sup>154,179,180,209</sup> Some studies cited no increased risk of malignancies among patients receiving anti-TNF- $\alpha$  therapies, whereas others cited a more than threefold higher risk; this topic is elegantly reviewed elsewhere.<sup>210,211</sup> Several reports cited lymphomas (typically non-Hodgkin) in patients receiving chronic TNF- $\alpha$  antagonists (particularly those receiving concomitant immunosuppressive therapy), but the overall risk is low.<sup>209,212-214</sup> A study of >19,000 RA patients (55% were treated with TNF- $\alpha$  antagonists) cited no higher risk of lymphoma among patients receiving anti-TNF- $\alpha$  antagonists compared with controls (no anti-TNF- $\alpha$  therapy) (OR = 1.0).<sup>209</sup> Even among patients receiving *both* MTX and TNF- $\alpha$  antagonists, the OR for lymphoma development was 1.1 compared with controls (not significant). The overall incidence of lymphoma in the entire cohort was 1.059 per 1000 patient-years. British investigators prospectively evaluated >14,000 RA patients receiving anti-TNF- $\alpha$  therapy ( $n=10,735$ ) and no other biologic agent; the comparison group received DMARDs ( $n=3,352$ ).<sup>180</sup> Within this group, 293 RA patients had a prior history of malignancy who were subsequently treated with either anti-TNF- $\alpha$  therapy ( $n=177$ ) or DMARDs ( $n=117$ ).<sup>180</sup> Among these 293 patients, 20 new cancers developed. The rates of new ("incident") malignancy were 25.3 events/1000 person-years in the anti-TNF- $\alpha$  cohort and 38.3/1000 person-years in the DMARD cohort, generating an age- and sex-adjusted incidence

rate ratio of 0.58 for the anti-TNF- $\alpha$  cohort compared with the DMARD cohort. Among patients with prior melanomas, three of 17 (18%) in the anti-TNF- $\alpha$  cohort developed an incident malignancy compared with 0 of 10 in the DMARD cohort. Data regarding malignancy risk in WG or AAV are limited. In the WGET study, 180 patients with WG were randomized to etanercept or placebo (both combined with conventional therapy).<sup>59</sup> Solid organ cancers developed in six of 89 patients in the etanercept group but in none of 91 control patients ( $p < 0.01$ ). All patients developing malignancy receiving CYC concomitantly.<sup>59</sup> Given the small sample size, conclusions are limited.

### Gonadal Toxicity and Teratogenesis

The effect of TNF- $\alpha$  inhibitors on gonadal function, reproductive capacity, or pregnancy is not known. Women should not breast feed their infants while receiving anti-TNF- $\alpha$  therapy.

### Cardiovascular

TNF- $\alpha$  antagonists may have deleterious effects on serum lipids (increases in cholesterol and HDL)<sup>215,216</sup> but some small studies in RA patients found no difference in progression of carotid vascular disease<sup>217</sup> or coronary atherosclerosis.<sup>217</sup> British investigators prospectively assessed the rates of myocardial infarction (MI) in 8670 RA patients treated with anti-TNF- $\alpha$  agents and 2170 RA patients treated with traditional DMARDs.<sup>218</sup> Sixty-three MIs occurred in the anti-TNF- $\alpha$  cohort during 13,233 person-years of follow-up compared with 17 MIs in the DMARD cohort during 2893 person-years of follow-up. After adjustment for baseline risk factors, there was no reduction in the MI risk in the anti-TNF- $\alpha$  cohort compared with the DMARD cohort. However, analysis of patients who responded to anti-TNF- $\alpha$  treatment within 6 months cited a lower incidence of MI rates (3.5 events/1000 person-years compared with 9.4 events/1000 person-years in the DMARD cohort). Two studies of etanercept in RA patients were terminated early when interim analysis showed a lack of efficacy.<sup>219</sup> More importantly, high-dose infliximab was deleterious in patients with moderate to severe heart failure.<sup>220</sup> Thus severe heart failure is a contraindication to anti-TNF- $\alpha$  therapy.<sup>216</sup>

### Miscellaneous Adverse Effects

Rarely, TNF- $\alpha$  inhibitors may cause demyelination (central and peripheral) syndromes<sup>221</sup> and other neurological manifestations [eg, optic neuritis,<sup>222</sup> multiple sclerosis (MS),<sup>223,224</sup> seizures,<sup>159,225</sup> and progressive multifocal leukoencephalopathy (PML)].<sup>221,226</sup> In a case series of 19 patients developing new onset demyelination during

anti-TNF- $\alpha$  therapy for arthritis, 17 patients were receiving etanercept and two were receiving infliximab.<sup>221</sup> Neurological manifestations may improve following prompt discontinuation of therapy.<sup>221</sup>

TNF- $\alpha$  inhibitors may be associated with acute infusion reactions (eg, with IV infliximab) or injection site reactions (typically pain, itching, erythema, or swelling) with subcutaneous etanercept or adalimumab.<sup>159</sup> Serious infusion reactions have been reported with infliximab (eg, hypotension, anaphylaxis) but are rare (< 1%).<sup>227</sup> Severe reactions mandate cessation of anti-TNF- $\alpha$  therapy. Mild to moderate infusion reactions may abate with slower infusion times, reducing the dose, or premedication with antihistamines, acetaminophen, and CSs.<sup>227</sup> Because infliximab is a chimeric antibody, autoantibodies develop in 15 to 50% of patients during the course of therapy; the concomitant use of MTX reduces the frequency of developing autoantibodies.<sup>227</sup> The rate of developing antibodies to other TNF- $\alpha$  inhibitors is lower (3 to 15%). Autoimmune disorders, with positive antinuclear antibodies (ANAs) and anti-double-stranded DNA antibody (dsDNA) may complicate therapy with TNF- $\alpha$  antagonists<sup>159,160</sup> and may lead to systemic lupus erythematosus (SLE),<sup>181</sup> lupus-like syndromes,<sup>228</sup> and leukocytoclastic vasculitis.<sup>229</sup> These manifestations may improve or resolve following discontinuation of therapy.<sup>181,229</sup>

## RITUXIMAB

CYC and CSs have been the mainstays of induction therapy for AAV. Unfortunately, this treatment is associated with high mortality and serious adverse events. Recent studies indicate that rituximab (RTX), an anti-CD20 monoclonal antibody, has similar safety and efficacy to CYC in the setting of AAV, at least in the short term. In an open-label, parallel-design, randomized trial, patients with newly diagnosed, severe AAV received *either* RTX with two doses of IV CYC and CS ( $n = 33$ ) *or* CYC and CS *without* RTX ( $n = 11$ ). Rates of sustained remission and severe adverse events were similar at 12 months in both groups.<sup>12</sup> Similar and complementary findings were described by Stone et al from a multicenter, double-blind, double-dummy, non-inferiority trial that randomly assigned patients with severe, newly diagnosed, or relapsing AAV to CS plus *either* RTX ( $n = 99$ ) *or* CYC ( $n = 98$ ). Similar proportions of patients achieved CS-free remission at 6 months, and adverse event rates did not differ between these groups. However, the RTX-based regimen more effectively induced remission in patients with relapsing disease; 34 of 51 such patients treated with RTX achieved CS-free remission, compared with 21 of 50 those treated with CYC.<sup>11</sup> Moreover, favorable responses have been noted with RTX as salvage therapy for patients failing conventional AAV therapy.<sup>230-243</sup>

RTX is a monoclonal antibody that targets CD20, a specific B cell surface antigen and was the first monoclonal antibody approved for the treatment of non-Hodgkin lymphoma.<sup>244</sup> The FDA approved RTX for the treatment of refractory low-grade lymphoma in 1997.<sup>245</sup> It has since been used for the treatment of several CD20-positive B cell malignancies.<sup>246,247</sup> The selectivity of this drug for B cells led to further investigations involving autoimmune B cell driven diseases, including multiple rheumatologic diseases (particularly RA); RTX is approved for the treatment of RA.<sup>248</sup> However, there are multiple off-label uses, including chronic lymphocytic leukemia (CLL), SLE, MS, autoimmune hemolytic anemia, posttransplant lymphoproliferative disorder, graft-versus-host-disease, allograft rejection, pemphigus vulgaris, chronic immune mediated thrombocytopenia, and Evans syndrome.<sup>249,250</sup>

## Mechanism of Action

RTX is a chimeric murine/human monoclonal immunoglobulin G1 antibody that targets the B cell differentiation marker CD20.<sup>251</sup> This B cell differentiation marker CD20 is a cell-surface marker specifically found on pre-B and mature B lymphocytes, but it is not found on the surface of most other cell types and is not free in the circulation.<sup>251,252</sup> Thus the predominant binding site for RTX is CD20 on B cells. The binding of RTX to cell surface CD20 results in destruction of the B cell by multiple mechanisms, including the induction of B cell apoptosis, complement-dependent cytotoxicity, and antibody-dependent cytotoxicity via opsonization with B cell destruction by mononuclear phagocytes and NK cells.<sup>251,252</sup>

## Administration

RTX is administered intravenously at a typical dose of 375 mg/m<sup>2</sup> once weekly for 4 weeks (most diseases) or at 1000 mg on days 1 and 15 for RA patients. Typically patients are premedicated with an antihistamine with or without methylprednisolone and acetaminophen. With oncology uses, a uricostatic agent (eg, allopurinol) and aggressive hydration are recommended for patients at risk of tumor lysis syndrome.

In patients with CLL, prophylaxis for PCP and herpes viruses is recommended during treatment (and for up to 6 to 12 months following treatment). In one study of AAV, patients treated with RTX also received CS and two pulses of IV CYC at initiation of therapy, but no additional maintenance therapy was given.<sup>12</sup> Whether RTX should be used with CS *alone* or CS *combined with* IV CYC has not been clarified.<sup>253</sup> The role for RTX long-term maintenance therapy in AAV has not been studied. Additional studies are required to assess indications for RTX, appropriate dosing and

frequency of administration, role for concomitant therapy, and long-term side effects.

The half-life of RTX ranges between 1.6 and 20 days, which is related to the dose and number of doses administered.<sup>254</sup> RTX remains detectable in the serum for up to 6 months after a single infusion. B cell depletion usually occurs by 2 weeks, and B cell recovery typically begins at 6 months and continues until 12 months.<sup>255,256</sup> Some patients may continue to have subtle abnormalities in B lymphocyte populations for several years following administration. Typically, patients postinfusion will require periodic laboratory follow-up with CBC, comprehensive metabolic panel, immunoglobulin levels, and lymphocyte counts/subpopulations. These results will vary depending on the patient, dose, indication, and duration of therapy. Importantly, if patients are found to have new neurologic or skin changes this needs to be evaluated because RTX has been associated with PML and severe mucocutaneous reactions.

### Side Effects

FDA boxed warnings on the package insert include (1) transfusion reaction resulting in anaphylaxis characterized by fever, hypotension, bronchospasm, urticaria, and angioedema (80% of cases are seen with the first infusion); (2) PML, a serious central nervous system infection, due to the JC virus, that usually occurs within 12 months of the first infusion and requires magnetic resonance imaging and spinal tap for diagnosis<sup>257</sup>; (3) severe mucocutaneous reactions resembling Stevens-Johnson reactions or toxic epidermal necrolysis; (4) if used for a malignancy the patient can develop tumor lysis syndrome typified by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia all of which can lead to acute renal failure; (5) opportunistic infections, including PCP and viral infections [eg, parvovirus B19, herpes zoster varicella (HZV), CMV, or herpes simplex virus (HSV)]<sup>258,259</sup>; (6) hepatitis secondary to reactivation of hepatitis B resulting in fulminant hepatitis and hepatic failure.

### Infusion-Related Reactions

Infusion-related reactions (defined as any adverse event reported during or within 24 hours of infusion) were higher with RTX versus placebo (29% vs 23%, respectively) during or following the first infusion.<sup>260,261</sup> Most of these reaction (eg, nasopharyngitis, pyrexia, hypertension, and dizziness) were of mild/moderate intensity and abated with further infusions. The signs and symptoms of acute infusion reactions (eg, pruritus, urticaria, rash, angioedema, fever, chills, rigors, sneezing, throat irritation/tightness, cough, bronchospasm, with or without hypotension or hypertension) were experienced by a

greater proportion of RTX-treated patients (23%) than placebo-treated patients (18%) during the first infusion.<sup>260,261</sup> However, the likelihood of patients experiencing a reaction diminished with subsequent infusions. Only two RTX-treated patients experienced acute infusion reactions that were considered serious adverse events (anaphylaxis and hypertension, respectively). Pre-medication with IV methylprednisolone (100 mg 30 minutes before each infusion) significantly reduced both the incidence and severity of acute infusion reactions.<sup>260,261</sup>

### Infections

There is some evidence suggesting that RTX, in addition to its effect on B cells, influences T cell immunity and predisposes to opportunistic infections.<sup>262</sup> Furthermore, the possible increased incidence of certain viral infections with the use of RTX supports the notion RTX may cause immunosuppression through several other mechanisms such as delayed-onset cytopenia, particularly neutropenia and hypogammaglobulinemia, especially when administered for long periods (eg, maintenance therapy).<sup>263–265</sup>

There are reports of an increased incidence of infections with RTX treatment in patients with lymphomas and RA.<sup>266–268</sup> Pooled data from 356 patients who received RTX monotherapy showed that the incidence rate of infectious events was 30%; 19% of patients had bacterial infections, 10% viral infections, 1% fungal infections, and 6% infections of unknown etiology. Severe infections, including sepsis, occurred in only 1% of patients during the treatment period, and in 2% during the follow-up period.<sup>269</sup> Another review involving 389 patients from 25 studies found the incidence of serious infections varied from 2.8 to 45% (mean 12.5%).<sup>249</sup> However, specific clinical trials will be required to determine the association of RTX with infections. In fact, many investigators suggest that infections in patients treated with RTX are likely a multifactorial process that is dependent on the patient's age, comorbidities, underlying disease, concurrent immunosuppression/chemotherapy, making the causal relationship between RTX and development of infection difficult to analyze.

With regard to bacterial infections there may be a small increase in serious bacterial infections in RA patients receiving RTX 1000 mg with or without a TNF- $\alpha$  blocking agent.<sup>267,270</sup> Overall, sinopulmonary infections are the most common bacterial infections that have been associated with the use of RTX, but further studies are needed.

In lymphoma clinical trials where a history of TB was not an exclusion criterion, no evidence of an increased incidence of TB was noted.<sup>266</sup> However, infection with other mycobacteria has rarely been associated

with RTX; thus physicians should remain cognizant of mycobacterial infections in patients receiving RTX.<sup>271</sup>

The most frequent viral infection complicating RTX therapy for lymphoma was hepatitis B virus (HBV) infection. HBV reactivation accounted for 39% of the reported cases, resulting in a high mortality of 52% due to hepatic failure; however, the increased risk is not clear with available data.<sup>265,266,272-275</sup> There are increasing reports of HBV reactivation following RTX therapy, either when used alone or in combination with chemotherapy.<sup>276</sup> In a recent study of lymphoma patients with prior resolved hepatitis B, among HB surface antigen (HBsAg)-negative/anti-HB core (HBc)-positive patients treated with RTX-CHOP, 25% developed HBV reactivation.<sup>277</sup> Some investigators suggest that the use of RTX in HBsAg-positive patients can be continued provided they receive a prophylactic antiviral for a prolonged duration (up to 6 months) after cessation of chemotherapy. Overall, HBV reactivation may occur in the setting of RTX use, and close monitoring of HBV DNA and LFTs during RTX therapy for at least 6 months after the completion of administration is required, with an alternative approach of prophylactic antiviral therapy to prevent liver complications.

RTX was reported to increase hepatitis C virus (HCV) viral load and alanine aminotransferase (ALT) levels in patients with HCV-related cryoglobulinemia and lymphoma.<sup>278,279</sup> Therefore, combined use of RTX with chemotherapy may lead to an additional risk for worsening of HCV infection. The influence of RTX on HCV replication is not well understood. Overall, the association of RTX with HCV infection remains complex (RTX may exacerbate HCV infection, but in other cases it has been used for the treatment of HCV-related autoimmune phenomena (eg, cryoglobulinemia).<sup>265,266,278,279</sup> Monitoring HCV viral load during RTX therapy may be important.

Infections with herpesviruses such as CMV, HZV, and HSV have been described in association with RTX use.<sup>265,266</sup> The most common herpesvirus associated with RTX is CMV.<sup>26,265</sup> However, more data are needed to establish the association of RTX with the development of herpes viral infections.

A recent study identified 57 patients with PML who had been treated with RTX.<sup>257</sup> Fifty-two patients had lymphoproliferative disorders; five had immune-mediated disorder (eg, SLE). All 57 patients had been treated with other aggressive immunosuppressives.<sup>257</sup> There are also reported cases of RTX-associated PML in RA. Case fatality rates were between 90 and 100% among those diagnosed with PML within 3 months of their last dose of RTX.<sup>257</sup> This may reflect the nature of the underlying disease and/or the inducible immune defect due to RTX. Determining the exact risk that RTX poses for the development of PML is difficult. For instance, the risk of PML with CLL may exceed 3%

even in the absence of RTX.<sup>280</sup> Interestingly, some investigators proposed that RTX after high-dose therapy and hematopoietic stem cell transplant delays the onset of PML.<sup>280</sup> Furthermore, PML has also been reported with SLE and RA in the absence of RTX with an incidence rate between (0.4 to 4)/100,000 hospital discharges, indicating that there is an increased risk of PML with these disorders.<sup>257,281-283</sup> PML occurs a median of 5.5 months after the last RTX dose, but the causal relationship between PML and RTX remains unclear.<sup>257,281-283</sup>

PCP pneumonia is a common and life-threatening complication of immunosuppressive therapy in AAV, in particular with CYC treatment.<sup>284</sup> PCP has been strongly linked to low T cell counts, especially in patients infected with the human immunodeficiency virus. Therefore, B cell depletion induced by RTX treatment is not commonly considered a PCP risk factor. However, there have been at least 35 patients reported to develop PCP following RTX, with ~75% of the patients having lymphoma and receiving other chemotherapies. The remaining were on or had recent other aggressive immunosuppression for immune-mediated diseases (eg, hemolytic anemia, refractory pemphigus, and AAV). Importantly, these cases seemed to be associated with suboptimal chemoprophylaxis with cotrimoxazole.<sup>285-288</sup> Although there are only a few reports of patients with PCP following RTX treatment, in the absence of evidence to the contrary, patients treated with RTX should be considered at an increased risk for PCP. In patients with AAV, we give PCP chemoprophylaxis.

### Pulmonary Toxicity

RTX infusion pulmonary toxicity is rare. It has been described as an alveolar-interstitial pneumonitis/pneumonia, pulmonary fibrosis, and cryptogenic organizing pneumonia. Some cases were lethal.<sup>289-294</sup> RTX-associated lung injury more commonly occurs in elderly patients with B cell malignancies. Future studies will be required to determine the exact incidence of this possible pulmonary complication of RTX use.

### Hematologic Toxicities

Generally, RTX-associated hematologic toxicities are transient and self-limited. Although an episode of delayed-onset neutropenia associated with RTX therapy has been reported,<sup>295</sup> acute thrombocytopenia is extremely rare.<sup>296</sup>

### Induction of Neoplasia

Among patients with exposure to RTX during the AAV trial,<sup>11</sup> malignant conditions developed in six of 124 (5%), as compared with one of 73 patients *without*

exposure to RTX; these differences were not statistically significant. With the exception of two cases of prostate cancer, all patients in whom malignant conditions developed had histories of exposure to at least two medications known to increase the risk of cancer (ie, CYC, AZA, or MTX). The specific types of solid malignant tumors among patients who received RTX were papillary thyroid cancer, uterine cancer, prostate cancer, colon cancer, bladder cancer, and lung cancer. More studies are required to determine whether there is any association between RTX therapy and the development of malignancies.

### Gonadal Toxicity and Teratogenesis

Very few cases of rituximab administration during pregnancy have been described. There are cases of rituximab administration during the first to third trimester of pregnancy in women with immune diseases. Some report short-term to no significant effects on B cell counts or the immune status of the newborn.<sup>297-299</sup> The impact of RTX on gonadal toxicity or teratogenesis needs further investigation.

### Monitoring Parameters

Screening for HBV and HCV in high-risk patients should be performed prior to initiation of RTX therapy. Carriers and patients with evidence of recovery from prior hepatitis infection should be monitored for clinical and laboratory signs of HBV and HCV infection during therapy and for up to a year following completion of treatment. CBC with differential and platelets should be obtained prior to treatment, at weekly to monthly intervals, and more frequently in patients with cytopenias. Some physicians advocate the monitoring of peripheral CD20 cells and immunoglobulins.

### HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN

IV immunoglobulin (IVIg) contains pooled immunoglobulins extracted from the plasma of blood donors and was originally used to treat immunodeficiencies. However, high-dose IVIg (up to 2 g/kg), alone or combined with immunosuppressive agents, has been shown to be efficacious in diverse autoimmune and inflammatory disorders,<sup>300</sup> including Kawasaki disease and AAV refractory to or intolerant of conventional therapy.<sup>2,17,301,302</sup> Trials comparing IVIg with other salvage therapies have not been done, and the place for IVIg in the treatment algorithm for AAV remains unclear. One randomized, controlled trial in patients with persistent WG or MPA compared a single course of IVIg (0.4 g/kg/day for 5 days) versus placebo combined with other immunosuppressant therapy.<sup>302</sup>

In this study, the IVIg group was more likely to achieve partial or complete remission at 3 months (82% vs 35%), but the benefit did not extend beyond 3 months. In another study, patients with relapsed WG or MPA were treated with IVIg (0.5 g/kg/day for 4 days) monthly for 6 months plus CSs added to stable doses of other immunosuppressant therapies.<sup>17</sup> Twenty-one out of 22 patients achieved remission between month 1 and month 5. However, seven patients had relapsed by month 9, and six additional patients relapsed between 9 and 24 months. Given the favorable safety and tolerability profile as compared with repeated cycles of CYC, high-dose IVIg can be considered in the therapeutic approach to AAV. However, future trials are required to determine optimal duration of IVIg and its use in place of, or in addition to, CS and other immunosuppressant therapies.

### Mechanism of Action

IVIg exerts myriad immunomodulatory effects.<sup>300</sup> The exact mechanisms for IVIg's effects in AAV are unclear, but proposed mechanisms include neutralization of pathogenic circulating autoantibodies (including AN-CAs), blockade of Fc receptors on phagocytic cells; downregulation of T- and B-cell function, preventing binding of activated complement components C3b and C4b, and modulating cytokine production.<sup>300,303</sup>

### Dosage, Route of Administration, Pharmacology

The published experience in AAV has used high-dose IVIg (2 g/kg/day divided over 4 or 5 days).<sup>17,301,302</sup> Remission has been reported with a single high-dose IVIg course as well monthly high-dose IVIg courses for 6 months, but relapses appear to be common beyond 3 months from the last IVIg treatment.<sup>17,302</sup> These findings suggest that IVIg may hold the disease in check, but maintenance therapy after discontinuation of IVIg, or possibly continued use of IVIg, may be necessary.

### Toxicity

IVIg is usually well tolerated, and side effects are generally mild and transient.<sup>300</sup> Adverse effects may be immediate or delayed.<sup>304</sup>

### Immediate Adverse Effects

Immediate undesirable effects include headache, chills, nausea, fatigue, myalgia, arthralgia, back pain, and change in blood pressure that occur within the first 30 minutes of infusion and may be relieved by slowing the infusion rate.<sup>304</sup> Premedication with analgesics, NSAIDs, antihistamines, or IV CSs may prevent these

symptoms.<sup>304</sup> Anaphylactoid reactions following IVIg administration are rare.<sup>304</sup>

### Delayed Adverse Effects

Severe late adverse effects are uncommon and mainly due to acute renal failure and thromboembolic events.

### Renal Toxicity

Nephrotoxicity may occur 1 to 10 days after initiation of IVIg treatment, especially in patients with preexisting renal disease, diabetes mellitus, and concomitant use of nephrotoxic drugs.<sup>304</sup> The pathology is usually completely reversible and consistent with osmotic injury, thought to be related to sucrose contained in some IVIg products.<sup>304</sup> For patients at increased risk of renal failure, sucrose-free IVIg products should be used.

### Hematologic Toxicity

Serious thromboembolic events following IVIg are most likely due to increased plasma viscosity following IVIg infusion.<sup>304</sup> The risk appears to be related to the rate of infusion. Lower daily doses and slower infusion rates (eg, 400 mg/kg/day over 8 to 12 hours for 5 days) may abrogate this effect. Neutropenia can also occur following IVIg infusion, but it is usually transient and not associated with increased infection risk.<sup>304</sup>

### Pulmonary Toxicity

Respiratory complications are usually attributable to volume overload or vasomotor/allergic reaction.<sup>304</sup>

### MONITORING

No monitoring is necessary or useful.

### REFERENCES

1. Frankel SK, Jayne D. The pulmonary vasculitides. *Clin Chest Med* 2010;31(3):519–536
2. Lynch JP III, White E, Tazelaar H, Langford CA. Wegener's granulomatosis: evolving concepts in treatment. *Semin Respir Crit Care Med* 2004;25(5):491–521
3. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. *Ann Intern Med* 1992;116(6):488–498
4. Jayne D, Rasmussen N, Andrassy K, et al; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. *N Engl J Med* 2003;349(1):36–44
5. Reinhold-Keller E, Fink CO, Herlyn K, Gross WL, De Groot K. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. *Arthritis Rheum* 2002;47(3):326–332
6. Pagnoux C, Mahr A, Hamidou MA, et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. *N Engl J Med* 2008; 359(26): 2790–2803
7. Sneller MC, Hoffman GS, Talar-Williams C, Kerr GS, Hallahan CW, Fauci AS. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. *Arthritis Rheum* 1995;38(5):608–613
8. Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. *Medicine (Baltimore)* 2007;86(5):269–277
9. Jayne D. Leflunomide versus methotrexate in Wegener's granulomatosis. *Rheumatology (Oxford)* 2007;46(7):1047–1048
10. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. *Curr Opin Rheumatol* 2008;20(2):131–137
11. Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med* 2010;363(3):221–232
12. Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. *N Engl J Med* 2010; 363(3):211–220
13. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. *Am J Kidney Dis* 2003;42(6):1149–1153
14. Wang CC, Shiang JC, Tsai MK, et al. Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis. *Clin Rheumatol* 2009;28(12):1457–1460
15. Stone JH, Uhlfelder ML, Hellmann DB, Crook S, Bedocs NM, Hoffman GS. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. *Arthritis Rheum* 2001;44(5): 1149–1154
16. Josselin L, Mahr A, Cohen P, et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. *Ann Rheum Dis* 2008;67(9):1343–1346
17. Martinez V, Cohen P, Pagnoux C, et al; French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. *Arthritis Rheum* 2008;58(1):308–317
18. Metzler C, Miehle N, Manger K, et al; German Network of Rheumatic Diseases. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. *Rheumatology (Oxford)* 2007;46(7):1087–1091
19. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. *Rheumatology (Oxford)* 2004; 43(3):315–320
20. Ghez D, Westeel PF, Henry I, Pruna A, Fournier A, Lassoued K. Control of a relapse and induction of long-term remission of Wegener's granulomatosis by cyclosporine. *Am J Kidney Dis* 2002;40(2):E6
21. Koenig CL, Hernández-Rodríguez J, Molloy ES, Clark TM, Hoffman GS. Limited utility of rapamycin in severe,



- refractory Wegener's granulomatosis. *J Rheumatol* 2009;36(1):116–119
22. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suárez LF, van der Woude FJ; European Vasculitis Study Group. Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. *Kidney Int* 2004;65(4):1440–1448
  23. Papo T, Le Thi Huong D, Wiederkehr JL, et al. Etoposide in Wegener's granulomatosis. *Rheumatology (Oxford)* 1999;38(5):473–475
  24. Flossmann O, Jayne DR. Long-term treatment of relapsing Wegener's granulomatosis with 15-deoxyspergualin. *Rheumatology (Oxford)* 2010;49(3):556–562
  25. Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). *Ann Rheum Dis* 2008;67(9):1322–1327
  26. Lockwood CM, Thiru S, Stewart S, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. *QJM* 1996;89(12):903–912
  27. Seror R, Pagnou C, Ruyvard M, et al; French Vasculitis Study Group. Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. *Ann Rheum Dis* 2010;69(12):2125–2130
  28. Meyer KC, Decker C, Baughman R. Toxicity and monitoring of immunosuppressive therapy used in systemic autoimmune diseases. *Clin Chest Med* 2010;31(3):565–588
  29. Marder W, McCune WJ. Advances in immunosuppressive therapy. *Semin Respir Crit Care Med* 2007;28(4):398–417
  30. Lynch JP III, McCune WJ. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. *Am J Respir Crit Care Med* 1997;155(2):395–420
  31. de Groot K, Harper L, Jayne DR, et al; EUVAS (European Vasculitis Study Group). Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. *Ann Intern Med* 2009;150(10):670–680
  32. Levitt M, Warr D, Yelle L, et al. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. *N Engl J Med* 1993;328(15):1081–1084
  33. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. *Am J Med* 1990;89(4):403–410
  34. Reinhold-Keller E, Kekow J, Schnabel A, et al. Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. *Arthritis Rheum* 1994;37(6):919–924
  35. Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. *Arthritis Rheum* 1997;40(12):2187–2198
  36. de Groot K, Adu D, Savage CO; EUVAS (European vasculitis study group). The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. *Nephrol Dial Transplant* 2001;16(10):2018–2027
  37. Wolverson SE, Remlinger K. Suggested guidelines for patient monitoring: hepatic and hematologic toxicity attributable to systemic dermatologic drugs. *Dermatol Clin* 2007;25(2):195–205, vi–ii
  38. Pedersen-Bjergaard J, Erbsøll J, Sørensen HM, et al. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. *Ann Intern Med* 1985;103(2):195–200
  39. Faurschou M, Sorensen JJ, Møller-Jensen L, et al. Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. *J Rheumatol* 2008;35(1):100–105
  40. Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses. *Am J Clin Oncol* 1994;17(6):522–526
  41. Du LT, Rigaud D, Papo T, Godeau P. Cyclophosphamide-induced hepatitis in Wegener's granulomatosis. *Mayo Clin Proc* 1994;69(9):912–913
  42. Snyder LS, Heigh RI, Anderson ML. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. *Mayo Clin Proc* 1993;68(12):1203–1204
  43. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. *Am J Respir Crit Care Med* 1996;154(6 Pt 1):1851–1856
  44. Cupps TR, Silverman GJ, Fauci AS. Herpes zoster in patients with treated Wegener's granulomatosis: a possible role for cyclophosphamide. *Am J Med* 1980;69(6):881–885
  45. Huynh-Do U, Gantenbein H, Binswanger U. Pneumocystis carinii pneumonia during immunosuppressive therapy for antineutrophil cytoplasmic autoantibody-positive vasculitis. *Arch Intern Med* 1995;155(8):872–874
  46. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. *Rheumatology (Oxford)* 2005;44(4):495–501
  47. Charlier C, Henegar C, Launay O, et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. *Ann Rheum Dis* 2009;68(5):658–663
  48. Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. *Best Pract Res Clin Rheumatol* 2009;23(3):391–401
  49. Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. *Ann Intern Med* 1996;124(5):477–484
  50. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide: long-term case-control follow-up study. *Am J Med* 1987;83(1):1–9
  51. Pedersen-Bjergaard J, Erbsøll J, Hansen VL, et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. *N Engl J Med* 1988;318(16):1028–1032
  52. Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a

- 20-year followup study. *Arthritis Rheum* 1995;38(8):1120-1127
53. Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. *J Natl Cancer Inst* 1995;87(7):524-530
  54. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. *Am J Med* 1985;78(1A):44-49
  55. Baltus JA, Boersma JW, Hartman AP, Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. *Ann Rheum Dis* 1983;42(4):368-373
  56. Schneider V, Kay S, Lee HM. Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. *Acta Cytol* 1983;27(3):220-224
  57. Knight A, Askling J, Ekblom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. *Int J Cancer* 2002;100(1):82-85
  58. Hesselstrand R, Scheja A, Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. *Ann Rheum Dis* 1998;57(11):682-686
  59. Stone JH, Holbrook JT, Marriott MA, et al; Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. *Arthritis Rheum* 2006;54(5):1608-1618
  60. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. *Cancer* 1977;39(4):1403-1409
  61. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. *Blood* 1981;58(4):849-851
  62. Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. *Arthritis Rheum* 2005;52(9):2761-2767
  63. Bermas BL, Hill JA. Effects of immunosuppressive drugs during pregnancy. *Arthritis Rheum* 1995;38(12):1722-1732
  64. Hoorweg-Nijman JJ, Delemarre-van de Waal HA, de Waal FC, Behrendt H. Cyclophosphamide-induced disturbance of gonadotropin secretion manifesting testicular damage. *Acta Endocrinol (Copenh)* 1992;126(2):143-148
  65. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. *Ann Intern Med* 1997;126(4):292-295
  66. Dow E, Schulman H, Agura E. Cyclophosphamide cardiac injury mimicking acute myocardial infarction. *Bone Marrow Transplant* 1993;12(2):169-172
  67. Bernatsky S, Ramsey-Goldman R, Clarke AE. Malignancies and cyclophosphamide exposure in Wegener's granulomatosis. *J Rheumatol* 2008;35(1):11-13
  68. Israel HL, Patchefsky AS, Saldana MJ. Wegener's granulomatosis, lymphomatoid granulomatosis, and benign lymphocytic angitis and granulomatosis of lung: recognition and treatment. *Ann Intern Med* 1977;87(6):691-699
  69. Weiner SR, Paulus HE. Treatment of Wegener's granulomatosis. *Semin Respir Med* 1989;10:156-161
  70. Weinblatt ME. Methotrexate for chronic diseases in adults. *N Engl J Med* 1995;332(5):330-331
  71. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005;52(8):2461-2469
  72. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. *Arthritis Rheum* 2000;43(8):1836-1840
  73. Langford CA, Sneller MC, Hoffman GS. Methotrexate use in systemic vasculitis. *Rheum Dis Clin North Am* 1997;23(4):841-853
  74. de Groot K, Mühler M, Reinhold-Keller E, Paulsen J, Gross WL. Induction of remission in Wegener's granulomatosis with low dose methotrexate. *J Rheumatol* 1998;25(3):492-495
  75. Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. *Arthritis Rheum* 1999;42(12):2666-2673
  76. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. *Inflammation* 1992;16(5):411-423
  77. de Groot K, Reinhold-Keller E, Tatis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis: methotrexate versus trimethoprim/sulfamethoxazole. *Arthritis Rheum* 1996;39(12):2052-2061
  78. Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. *Rheumatology (Oxford)* 2005;44(1):61-66
  79. van Ede AE, Laan RF, Rood MJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2001;44(7):1515-1524
  80. Morgan SL, Baggott JE, Vaughn WH, et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. *Ann Intern Med* 1994;121(11):833-841
  81. MacKinnon SK, Starkebaum G, Willkens RF. Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis. *Semin Arthritis Rheum* 1985;15(2):119-126
  82. Thomas DR, Dover JS, Camp RD. Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. *J Am Acad Dermatol* 1987;17(6):1055-1056
  83. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. *Am J Med* 1991;90(6):711-716
  84. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited: effects of long-term treatment in psoriasis. *Br J Dermatol* 1994;130(2):204-210
  85. Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose

- methotrexate for rheumatoid arthritis. *Arthritis Rheum* 1993;36(3):329-335
86. Bergquist SR, Felson DT, Prashker MJ, Freedberg KA. The cost-effectiveness of liver biopsy in rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum* 1995; 38(3):326-333
  87. Kremer JM, Alarcón GS, Lightfoot RW Jr, et al; American College of Rheumatology. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. *Arthritis Rheum* 1994;37(3):316-328
  88. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. *Am J Med* 2003;114(6):463-469
  89. Zisman DA, McCune WJ, Tino G, Lynch JP III. Drug-induced pneumonitis: the role of methotrexate. *Sarcoidosis Vasc Diffuse Lung Dis* 2001;18(3):243-252
  90. Carroll GJ, Thomas R, Phatouros CC, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. *J Rheumatol* 1994;21(1):51-54
  91. White DA, Rankin JA, Stover DE, Gellene RA, Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder. *Am Rev Respir Dis* 1989; 139(1):18-21
  92. Alarcón GS, Kremer JM, Macaluso M, et al; Methotrexate-Lung Study Group. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: a multicenter, case-control study. *Ann Intern Med* 1997;127(5): 356-364
  93. Dawson JK, Graham DR, Desmond J, Fewins HE, Lynch MP. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. *Rheumatology (Oxford)* 2002; 41(3):262-267
  94. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum* 1997;40(10):1829-1837
  95. Jones G, Mierins E, Karsh J. Methotrexate-induced asthma. *Am Rev Respir Dis* 1991;143(1):179-181
  96. LeMense GP, Sahn SA. Opportunistic infection during treatment with low dose methotrexate. *Am J Respir Crit Care Med* 1994;150(1):258-260
  97. Morice AH, Lai WK. Fatal varicella zoster infection in a severe steroid dependent asthmatic patient receiving methotrexate. *Thorax* 1995;50(11):1221-1222
  98. Moder KG, Tefferi A, Cohen MD, Menke DM, Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study. *Am J Med* 1995;99(3):276-281
  99. Nyfors A, Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics: a preliminary study. *Dermatologica* 1983;167(5):260-261
  100. Kamel OW, van de Rijn M, LeBrun DP, Weiss LM, Warnke RA, Dorfman RF. Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression. *Hum Pathol* 1994;25(7): 638-643
  101. Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. *J Rheumatol* 1992;19(9):1462-1465
  102. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. *J Rheumatol* 1991;18(8):1172-1175
  103. Hausknecht RU. Methotrexate and misoprostol to terminate early pregnancy. *N Engl J Med* 1995;333(9):537-540
  104. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. *Teratology* 1993;47(6):533-539
  105. Kozłowski RD, Steinbrunner JV, MacKenzie AH, Clough JD, Wilke WS, Segal AM. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease. *Am J Med* 1990;88(6):589-592
  106. Blackburn WD Jr, Alarcón GS. Impotence in three rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum* 1989;32(10):1341-1342
  107. Hoffman GS. "Wegener's granulomatosis": the path traveled since 1931. *Medicine (Baltimore)* 1994;73(6):325-329
  108. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. *Ann Intern Med* 1983; 98(1):76-85
  109. Hellmich B, Lamprecht P, Gross WL. Advances in the therapy of Wegener's granulomatosis. *Curr Opin Rheumatol* 2006;18(1):25-32
  110. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. *Arthritis Rheum* 1998;41(10):1858-1866
  111. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. *Gut* 1993;34(8):1081-1085
  112. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. *Ann Intern Med* 1989;111(8):641-649
  113. Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis: a national post-marketing perspective. *Arthritis Rheum* 1989;32(7):837-843
  114. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. *Arthritis Rheum* 1995; 38(1):142-145
  115. Adler M, Delhay M, Deprez C, et al. Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature. *Nephrol Dial Transplant* 1987;2(3): 183-188
  116. Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. *Hepatology* 1991; 14(5):806-810
  117. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. *Gastroenterology* 2003;125(2): 298-303
  118. Refabert L, Sinnassamy P, Leroy B, Fauroux B, de Blic J, Bensman A. Azathioprine-induced pulmonary haemorrhage

- in a child after renal transplantation. *Pediatr Nephrol* 1995; 9(4):470–473
119. Bottomley WW, Ford G, Cunliffe WJ, Cotterill JA. Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. *Br J Dermatol* 1995; 133(3):460–462
  120. Balachandran I, Galagan KS. Cervical carcinoma in situ associated with azathioprine therapy: a case report and literature review. *Acta Cytol* 1984;28(6):699–702
  121. Wilkinson AH, Smith JL, Hunsicker LG, et al. Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. *Transplantation* 1989;47(2):293–296
  122. Silman AJ, Petrie J, Hazleman B, Evans SJ. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. *Ann Rheum Dis* 1988;47(12):988–992
  123. Tage-Jensen U, Schlichting P, Thomsen HF, Høybye G, Thomsen AC. Malignancies following long-term azathioprine treatment in chronic liver disease: a report from the Copenhagen Study Group for Liver Diseases. *Liver* 1987; 7(2):81–83
  124. Kinlen LJ. Malignancy in autoimmune diseases. *J Autoimmun* 1992;5(suppl A):363–371
  125. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. *Lancet* 1994;343(8908):1249–1252
  126. Amato MP, Pracucci G, Ponziani G, Siracusa G, Fratiglioni L, Amaducci L. Long-term safety of azathioprine therapy in multiple sclerosis. *Neurology* 1993;43(4):831–833
  127. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. *J Am Soc Nephrol* 1998;9(5):842–852
  128. Voogd CE. Azathioprine, a genotoxic agent to be considered non-genotoxic in man. *Mutat Res* 1989;221(2):133–152
  129. Kirk EP. Organ transplantation and pregnancy: a case report and review. *Am J Obstet Gynecol* 1991;164(6 Pt 1):1629–1633, discussion 1633–1634
  130. DeWitte DB, Buick MK, Cyran SE, Maisels MJ. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. *J Pediatr* 1984;105(4):625–628
  131. Nowack R, Göbel U, Klooker P, Hergesell O, Andrassy K, van der Woude FJ. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. *J Am Soc Nephrol* 1999;10(9):1965–1971
  132. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. *Arthritis Rheum* 2004;51(2): 278–283
  133. Iatrou C, Zerbala S, Revela I, et al. Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. *Clin Nephrol* 2009;72(1):31–37
  134. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. *Nephrol Dial Transplant* 2005;20(12):2725–2732
  135. Appel GB, Contreras G, Dooley MA, et al; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. *J Am Soc Nephrol* 2009;20(5):1103–1112
  136. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2007;2(5):968–975
  137. Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. *Transplantation* 2009;87(6):785–794
  138. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. *Lancet* 1995;345(8961):1321–1325
  139. Bove AA, Kashem A, Cross RC, et al. Factors affecting survival after heart transplantation: comparison of pre- and post-1999 listing protocols. *J Heart Lung Transplant* 2006; 25(1):42–47
  140. Kobashigawa JA, Miller LW, Russell SD, et al; Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. *Am J Transplant* 2006;6(6): 1377–1386
  141. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. *Nephrol Dial Transplant* 2008;23(4):1307–1312
  142. Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. *JAMA* 2010;304:2381–2388
  143. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. *Immunopharmacology* 2000;47(2-3):85–118
  144. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. *N Engl J Med* 2004;350(10):971–980
  145. Nogueras F, Espinosa MD, Mansilla A, Torres JT, Cabrera MA, Martín-Vivaldi R. Mycophenolate mofetil-induced neutropenia in liver transplantation. *Transplant Proc* 2005; 37(3):1509–1511
  146. Kobashigawa JA, Renlund DG, Gerosa G, et al; ERL2401 Heart Study Investigators. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, Myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. *J Heart Lung Transplant* 2006;25(8):935–941
  147. Salvadori M, Holzer H, de Mattos A, et al; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. *Am J Transplant* 2004;4(2): 231–236
  148. Darji P, Vijayaraghavan R, Thiagarajan CM, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders. *Transplant Proc* 2008; 40(7):2262–2267
  149. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. *J Infect Dis* 1997;175(4):901–904

150. Husain S, Singh N. The impact of novel immunosuppressive agents on infections in organ transplant recipients and the interactions of these agents with antimicrobials. *Clin Infect Dis* 2002;35(1):53–61
151. Kaczmarek I, Bigdeli AK, Vogeser M, et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. *Ther Drug Monit* 2008;30(4):419–427
152. McCune WJ. Mycophenolate mofetil for lupus nephritis. *N Engl J Med* 2005;353(21):2282–2284
153. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. *Ther Drug Monit* 2006;28(2):145–154
154. Patel RV, Clark LN, Leibold M, Weinberg JM. Treatments for psoriasis and the risk of malignancy. *J Am Acad Dermatol* 2009;60(6):1001–1017
155. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor- $\alpha$  blockade in chronic granulomatous disease-related colitis. *Clin Infect Dis* 2010;51(12):1429–1434
156. Helbling D, Breitbart TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumor necrosis factor therapy. *Eur J Gastroenterol Hepatol* 2002;14(12):1393–1395
157. Lee TW, Fedorak RN. Tumor necrosis factor- $\alpha$  monoclonal antibodies in the treatment of inflammatory bowel disease: clinical practice pharmacology. *Gastroenterol Clin North Am* 2010;39(3):543–557
158. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis* 2004;38(9):1261–1265
159. Langford CA. Biologic immunomodulatory therapies in the vasculitic diseases. *Semin Respir Crit Care Med* 2004;25(5):595–607
160. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. *Curr Opin Pharmacol* 2010;10(3):308–315
161. Karampetsou MP, Liossis SN, Sfikakis PP. TNF- $\alpha$  antagonists beyond approved indications: stories of success and prospects for the future. *QJM* 2010;103(12):917–928
162. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. *Curr Dir Autoimmun* 2010;11:180–210
163. Cantini F, Niccoli L, Salvarani C, Padula A, Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. *Arthritis Rheum* 2001;44(12):2933–2935
164. Tan AL, Holdsworth J, Pease C, Emery P, McGonagle D. Successful treatment of resistant giant cell arteritis with etanercept. *Ann Rheum Dis* 2003;62(4):373–374
165. Sfikakis PP, Theodossiadi PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease. *Lancet* 2001;358(9278):295–296
166. Sari I, Birlik M, Gonen C, et al. Cytomegalovirus colitis in a patient with Behçet's disease receiving tumor necrosis factor alpha inhibitory treatment. *World J Gastroenterol* 2008;14(18):2912–2914
167. Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss-syndrome (CSS) by TNF-alpha blockade. *Immunobiology* 2002;206(5):496–501
168. White ES, Lynch JP. Pharmacological therapy for Wegener's granulomatosis. *Drugs* 2006;66(9):1209–1228
169. Mukhtyar C, Luqmani R. Current state of tumour necrosis factor alpha blockade in Wegener's granulomatosis. *Ann Rheum Dis* 2005;64(suppl 4):iv31–iv36
170. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. *N Engl J Med* 2005;352(4):351–361
171. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. *Rheumatology (Oxford)* 2002;41(10):1126–1132
172. Booth AD, Jefferson HJ, Ayliffe W, Andrews PA, Jayne DR. Safety and efficacy of TNFalpha blockade in relapsing vasculitis. *Ann Rheum Dis* 2002;61(6):559
173. Booth A, Harper L, Hammad T, et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. *J Am Soc Nephrol* 2004;15(3):717–721
174. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. *Rheumatology (Oxford)* 2002;41(11):1303–1307
175. Hermann J, Reittner P, Scarpatetti M, Graninger W. Successful treatment of meningeal involvement in Wegener's granulomatosis with infliximab. *Ann Rheum Dis* 2006;65(5):691–692
176. Seror R, Mahr A, Ramanoelina J, Pagnoux C, Cohen P, Guillevin L. Central nervous system involvement in Wegener granulomatosis. *Medicine (Baltimore)* 2006;85(1):54–65
177. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. *Br J Ophthalmol* 2005;89(11):1542
178. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. *Arthritis Rheum* 2007;56(9):2896–2904
179. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA* 2006;295(19):2275–2285
180. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP; British Society For Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. *Arthritis Care Res (Hoboken)* 2010;62(6):755–763
181. Ramos-Casals M, Brito-Zerón P, Muñoz S, et al. Auto-immune diseases induced by TNF-targeted therapies: analysis of 233 cases. *Medicine (Baltimore)* 2007;86(4):242–251
182. Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Influence of anti-TNF

- therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2010;69(6):1086–1091
183. Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. *Chest* 2003;124(1):177–185
  184. Baughman RP, Drent M, Kavuru M, et al; Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. *Am J Respir Crit Care Med* 2006;174(7):795–802
  185. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. *J Rheumatol* 2003;30(8):1864–1867
  186. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. *Chest* 2005;127(3):1064–1071
  187. Baughman RP, Lower EE. Novel therapies for sarcoidosis. *Semin Respir Crit Care Med* 2007;28(1):128–133
  188. Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. *Respirology* 2009;14(4):522–528
  189. Raghu G, Brown KK, Costabel U, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. *Am J Respir Crit Care Med* 2008;178(9):948–955
  190. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. *Eur Respir J* 2004;24(4):708
  191. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. *Clin Exp Rheumatol* 2007;25(1):23–28
  192. Ostör AJ, Chilvers ER, Somerville MF, et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. *J Rheumatol* 2006;33(3):622–628
  193. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. *Arthritis Rheum* 2002;47(6):670–671
  194. Lindsay K, Melsom R, Jacob BK, Mestry N. Acute progression of interstitial lung disease: a complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. *Rheumatology (Oxford)* 2006;45(8):1048–1049
  195. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fibrosis. *Rheumatology (Oxford)* 2006;45(10):1312–1313
  196. Schoe A, van der Laan-Baalbergen NE, Huizinga TW, Breedveld FC, van Laar JM. Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab. *Arthritis Rheum* 2006;55(1):157–159
  197. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum* 2007;56(4):1125–1133
  198. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345(15):1098–1104
  199. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. *JAMA* 2009;301(7):737–744
  200. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. *Gut* 2004;53(9):1363–1365
  201. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. *Dig Dis Sci* 2007;52(6):1481–1484
  202. Warris A, Bjørnekleit A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. *N Engl J Med* 2001;344(14):1099–1100
  203. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? *Infect Control Hosp Epidemiol* 2003;24(7):477–482
  204. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. *J Rheumatol* 2002;29(7):1561–1563
  205. Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. *Nat Clin Pract Gastroenterol Hepatol* 2008;5(5):283–287
  206. Williams G, Khan AA, Schweiger F. Listeria meningitis complicating infliximab treatment for Crohn's disease. *Can J Infect Dis Med Microbiol* 2005;16(5):289–292
  207. Martin-Mola E, Balsa A. Infectious complications of biologic agents. *Rheum Dis Clin North Am* 2009;35(1):183–199
  208. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. *Ann Rheum Dis* 2010;69(7):1352–1355
  209. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. *Arthritis Rheum* 2007;56(5):1433–1439
  210. Askling J, Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. *Curr Opin Rheumatol* 2008;20(3):334–339
  211. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. *Arthritis Rheum* 2007;56(9):2886–2895
  212. Lakatos PL, Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD? *Curr Drug Targets* 2010;11(2):179–186
  213. Mariette X. Lymphoma, rheumatoid arthritis, and TNF-alpha antagonists. *Joint Bone Spine* 2010;77(3):195–197
  214. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. *Arthritis Rheum* 2002;46(12):3151–3158
  215. Dixon WG, Symmons DP. What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. *Ann Rheum Dis* 2007;66(9):1132–1136
  216. Atzeni F, Turiel M, Caporali R, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. *Autoimmun Rev* 2010;9(12):835–839
  217. Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. *Scand J Rheumatol* 2009;38(1):6–10

218. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum* 2007;56(9):2905–2912
219. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. *Int J Cardiol* 2002;86(2-3):123–130
220. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- $\alpha$ , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003;107(25):3133–3140
221. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum* 2001;44(12):2862–2869
222. Chung JH, Van Stavern GP, Frohman LP, Turbin RE. Adalimumab-associated optic neuritis. *J Neurol Sci* 2006;244(1-2):133–136
223. Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. *J Clin Gastroenterol* 2005;39(4):303–306
224. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. *J Rheumatol* 2007;34(1):239–240, discussion 240
225. Bechtel M, Sanders C, Bechtel A. Neurological complications of biologic therapy in psoriasis: a review. *J Clin Aesthet Dermatol* 2009;2(11):27–32
226. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. *Mod Rheumatol* 2007;17(1):72–74
227. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. *Gastroenterology* 2004;126(6):1593–1610
228. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. *Semin Arthritis Rheum* 2008;37(6):381–387
229. Mohan N, Edwards ET, Cupps TR, et al. Leukocytoclastic vasculitis associated with tumor necrosis factor- $\alpha$  blocking agents. *J Rheumatol* 2004;31(10):1955–1958
230. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. *Rheumatology (Oxford)* 2006;45(11):1432–1436
231. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. *Ann Rheum Dis* 2006;65(7):853–858
232. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2005;52(1):262–268
233. Memet B, Rudinskaya A, Krebs T, Oelberg D. Wegener granulomatosis with massive intracerebral hemorrhage: remission of disease in response to rituximab. *J Clin Rheumatol* 2005;11(6):314–318
234. Tamura N, Matsudaira R, Hirashima M, et al. Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. *Intern Med* 2007;46(7):409–414
235. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. *Arthritis Rheum* 2001;44(12):2836–2840
236. Omdal R, Wildhagen K, Hansen T, Gunnarsson R, Kristoffersen G. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. *Scand J Rheumatol* 2005;34(3):229–232
237. Brihaye B, Aouba A, Pagnoux C, Cohen P, Lacassin F, Guillevin L. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. *Clin Exp Rheumatol* 2007;25(1, suppl 44):S23–S27
238. Hermle T, Goestemeyer AK, Sweny P, Burns A. Successful therapeutic use of rituximab in refractory Wegener's granulomatosis after renal transplantation. *Clin Nephrol* 2007;68(5):322–326
239. Roccatello D, Baldovino S, Alpa M, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. *Clin Exp Rheumatol* 2008;26(3, suppl 49):S67–S71
240. Sharma A, Kumar S, Wanchu A, et al. Successful treatment of hypertrophic pachymeningitis in refractory Wegener's granulomatosis with rituximab. *Clin Rheumatol* 2010;29(1):107–110
241. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. *Arthritis Rheum* 2009;60(5):1540–1547
242. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2009;60(7):2156–2168
243. Martinez Del Pero M, Chaudhry A, Jones RB, Sivasothy P, Jani P, Jayne D. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. *Clin Otolaryngol* 2009;34(4):328–335
244. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. *Br J Cancer* 2003;89(8):1389–1394
245. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J Clin Oncol* 1998;16(8):2825–2833
246. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. *Blood* 2005;105(4):1417–1423
247. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346(4):235–242
248. Selewski DT, Shah GV, Mody RJ, Rajdev PA, Mukherji SK. Rituximab (Rituxan). *AJNR Am J Neuroradiol* 2010;31(7):1178–1180

249. Gürçan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR. A review of the current use of rituximab in autoimmune diseases. *Int Immunopharmacol* 2009;9(1):10–25
250. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med* 2008;358(7):676–688
251. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* 1994;83(2):435–445
252. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. *Am J Transplant* 2006;6(5 Pt 1):859–866
253. Falk RJ, Jennette JC. Rituximab in ANCA-associated disease. *N Engl J Med* 2010;363(3):285–286
254. Ng CM, Bruno R, Combs D, Davies B. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. *J Clin Pharmacol* 2005;45(7):792–801
255. Adeli MM, Eichner BH, Thornburg C, Williams L. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. *Pediatr Hematol Oncol* 2009;26(8):566–572
256. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. *Lancet* 2001;358(9292):1511–1513
257. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. *Blood* 2009;113(20):4834–4840
258. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and pretransplantation rituximab. *Blood* 2002;99(4):1486–1488
259. Shelton E, Yong M, Cohn S. Late onset *Pneumocystis pneumonia* in patients receiving rituximab for humoral renal transplant rejection. *Nephrology (Carlton)* 2009;14(7):696–699
260. Cohen SB, Emery P, Greenwald MW, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis Rheum* 2006;54(9):2793–2806
261. van Vollenhoven RF, Emery P, Bingham CO III, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. *J Rheumatol* 2010;37(3):558–567
262. Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. *Arthritis Rheum* 2005;52(2):501–513
263. Lim SH, Esler WV, Zhang Y, et al. B-cell depletion for 2 years after autologous stem cell transplant for NHL induces prolonged hypogammaglobulinemia beyond the rituximab maintenance period. *Leuk Lymphoma* 2008;49(1):152–153
264. Cattaneo C, Spedini P, Casari S, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. *Leuk Lymphoma* 2006;47(6):1013–1017
265. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. *Leuk Lymphoma* 2007;48(7):1307–1312
266. Aksoy S, Dizdar O, Hayran M, Harputluoglu H. Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis. *Leuk Lymphoma* 2009;50(3):357–365
267. Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Ann Rheum Dis* 2008;67(suppl 3):iii2–iii25(erratum in *Ann Rheum Dis* 2009;68(3):452, Kavanaugh A [added])
268. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. *Cancer* 2007;109(11):2182–2189
269. Kimby E. Tolerability and safety of rituximab (MabThera). *Cancer Treat Rev* 2005;31(6):456–473
270. Genovese MC, Breedveld FC, Emery P, et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. *Ann Rheum Dis* 2009;68(12):1894–1897
271. Lutt JR, Pisculli ML, Weinblatt ME, Deodhar A, Winthrop KL. Severe nontuberculous mycobacterial infection in 2 patients receiving rituximab for refractory myositis. *J Rheumatol* 2008;35(8):1683–1685
272. Özgönenel B, Moonka D, Savaan S. Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B-cell lymphoma. *Am J Hematol* 2006;81(4):302
273. Tsutsumi Y, Tanaka J, Kawamura T, et al. Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. *Ann Hematol* 2004;83(1):58–60
274. Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. *Ann Hematol* 2008;87(4):325–327
275. Wang F, Xu RH, Luo HY, et al. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. *BMC Cancer* 2008;8:115
276. Lok AS. Navigating the maze of hepatitis B treatments. *Gastroenterology* 2007;132(4):1586–1594
277. Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. *Ann Oncol* 2009;20(12):2013–2017
278. Fabrizi F, Martin P, Elli A, et al. Hepatitis C virus infection and rituximab therapy after renal transplantation. *Int J Artif Organs* 2007;30(5):445–449
279. Ennishi D, Terui Y, Yokoyama M, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. *Am J Hematol* 2008;83(1):59–62
280. García-Suárez J, de Miguel D, Krsnik I, Bañas H, Arribas I, Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. *Am J Hematol* 2005;80(4):271–281
281. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. *Neurol Clin* 1984;2(2):299–313



282. Marzocchetti A, Wuthrich C, Tan CS, et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. *J Neurovirol* 2008;14(5):455–458
283. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? *Autoimmun Rev* 2008;8(2):144–146
284. Ward MM, Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. *Arthritis Rheum* 1999;42(4):780–789
285. Hugel B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. *Arthritis Care Res (Hoboken)* 2010;62(11):1661–1664
286. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. *Isr Med Assoc J* 2002;4(11):1006–1008
287. Mukhtyar C, Guillevin L, Cid MC, et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. *Ann Rheum Dis* 2009;68(3):310–317
288. Teichmann LL, Woencckhaus M, Vogel C, Salzberger B, Schölmerich J, Fleck M. Fatal pneumocystis pneumonia following rituximab administration for rheumatoid arthritis. *Rheumatology (Oxford)* 2008;47(8):1256–1257
289. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. *Leuk Lymphoma* 2004;45(11):2321–2325
290. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin CJr, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. *Clin Lymphoma* 2003;4(1):36–42
291. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. *Respiration* 2008;76(4):449–453
292. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. *Mayo Clin Proc* 2004;79(7):949–953, 953
293. Schlesinger C, Koss MN. The organizing pneumonias: an update and review. *Curr Opin Pulm Med* 2005;11(5):422–430
294. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. *Am J Hematol* 2007;82(10):916–919
295. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. *Br J Haematol* 2003;121(6):913–918
296. Yi JH, Kim SJ, Ahn HK, Lee SJ, Chang MH, Kim WS. Rituximab-induced acute thrombocytopenia: a case report and review of the literature. *Med Oncol* 2009;26(1):45–48
297. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. *Clin Dev Immunol* 2008;2008:271363
298. Ojeda-Urbe M, Gilliot C, Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. *J Perinatol* 2006;26(4):252–255
299. Østensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. *Rheumatology (Oxford)* 2008;47(suppl 3):iii28–iii31
300. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. *N Engl J Med* 2001;345(10):747–755
301. Ito-Ihara T, Ono T, Nogaki F, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. *Nephron Clin Pract* 2006;102(1):c35–c42
302. Jayne DR, Chapel H, Adu D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. *QJM* 2000;93(7):433–439
303. Chung SA, Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. *Curr Opin Rheumatol* 2009;21(1):3–9
304. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. *Clin Rev Allergy Immunol* 2005;29(3):173–184